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1.1. Critical illness 
 
Critical illness is the state in which the patient has to rely on intensive and advanced medical support 
to survive. Mechanical devices such as ventilators, dialysis machines and extra-corporeal membrane 
oxygenators, together with pharmacological agents are the core of his medical support. The cause of 
this critical illness may result from trauma, severe infection, major surgery and exacerbations of 
medical disease. This technological advance in the 1950 and 1960’s allowed critically ill patients to 
survive beyond the acute phase of critical illness. Patients did not any more die of respiratory failure, 
uremic coma and hemodynamic collapse. Prolonged critical illness has been in fact the consequence 
of our medical improvements: a ‘disease of medical progress’ [1]. HIV/AIDS and cancer have also 
seen the evolution from acute death to chronic illness, on a different time scale though. 
 
The distinction between acute and prolonged critical illness has been underpinned by the 
characterization of two distinctive inflammatory, metabolic and neuroendocrine paradigms [2-5]. In 
the acute phase of critical illness, patients are generally confronted with a strong inflammatory 
response, hypermetabolism, catabolism and activation of the anterior pituitary gland (such as TSH 
and GH) and resistance to its downstream hormones (such as T3 and IGF-I). When the patient is 
entering the prolonged phase of critical illness, the systemic inflammation is more moderate, going 
together with a continuing catabolism but this time with a decreased metabolic rate. The 
neuroendocrine system is now characterized by an exhaustion of the anterior pituitary gland and a 
restored sensitivity of the peripheral tissues to the downstream hormones of the anterior pituitary 
gland. Attempts to extrapolate endocrine treatment strategies, such as GH supplementation, from 
the acute to the prolonged phase of critical illness have failed. Likewise, extending the dearly needed 
aggressive interventions from the acute ‘shock’ phase into the prolonged phase have been 
disappointing across the board. Striving for supranormal oxygen delivery by aggressive hemodynamic 
support and red blood cell transfusions, aggressive mechanical ventilation and long antibiotic 
treatments have all negatively impacted patient outcome [6]. Some authors claim that the metabolic 
shutdown, and the ensuing organ dysfunction, in the prolonged phase of critical illness can be 
regarded as a hibernation-type response, which may be adaptive [5]. Therefore, prolonged critical 
illness is tightly linked to the Multiple Organ Dysfunction Syndrome (MODS). This new clinical 
syndrome emerged in critically ill patients in the early 1970’s. After major emergency surgery, many 
patients experienced a progressive failure of multiple organs, often in a similar pattern: respiratory 
failure, hypotension, renal failure, jaundice and gastrointestinal bleeding. In a consensus conference 
in 1991 MODS was defined as ‘the presence of altered organ function in an acutely ill patient such 
that homeostasis cannot be maintained without intervention’ [7, 8]. 
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There is nowadays a consensus among clinicians that acute and prolonged critical illness are different 
entities not only from a pathophysiological point of view but equally from the way it should be 
approached to treat the underlying pathophysiological mechanisms. 
 
 
1.2. ICU jaundice: more than sepsis-induced cholestasis? 
 
While jaundice and hepatic dysfunction have always been consistently present in MODS since the 
first descriptions in the early seventies, its definition, etiology, treatment have been lagging behind 
[9, 10]. Overt ICU jaundice, hallmarked by the yellow discoloration of the skin and the corneas and 
elevated serum bilirubin levels, has been typically associated with prolonged critical illness [11]. The 
presence of ICU jaundice has a strong association with increased ICU mortality [12]. Several 
contributing factors for ICU jaundice have been identified [13]. Sepsis is the main cause of this 
complication, certainly when it originates from intra-abdominal infections by Gram-negative 
bacteria. However, also pneumonia and endocarditis have been commonly linked to ICU jaundice. 
Moreover, the antibiotics to treat these infections during sepsis may contribute themselves to the 
ICU jaundice. For basically all antibiotics cholestatic liver dysfunction has been described: beta-
lactam antibiotics, carbapenems, fluoroquinolones, glycopeptides, cephalosporines and antifungals. 
An increase of the bilirubin load through hemolysis certainly aggravates ICU jaundice. The most 
common causes of discrete hemolysis are polytransfusion, the transfusion of older red blood cells, 
resorption of hematomas, hypersplenism, and hemolysis in circulatory support machines such as the 
ECMO.  
 
Hepatic ischemia and hepatocellular necrosis, during the early phase of critical illness herald the 
genesis of ICU jaundice in the prolonged phase of critical illness [11]. Hepatic ischemia in cardio-
circulatory shock often leads to ischemic hepatitis. This ischemic hepatitis is characterized by a steep 
increase in serum AST and ALT concentrations (> 5-10x the upper limit of normality) [14]. While, this 
rarely results in hepatic failure and decreased hepatic synthesis capacity, it is almost invariably 
followed by rising bilirubin levels. Overt hepatocellular necrosis occurs less frequently in critically ill 
patients.  
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1.3. The role of parenteral nutrition 
 
A final factor, often involved in ICU jaundice, is the prolonged administration of parenteral nutrition 
[15]. Although the precise etiology is still unknown, a combination of toxicity of parenteral nutrition, 
a lack of enteral nutrition and the presence of sepsis and frequent infectious episodes have been 
suggested. As hepatic immaturity also contributes to the development of parenteral nutrition 
associated cholestasis, it is inevitably more prevalent in neonates and infants [16]. The clinical 
presentation is steady rise in conjugated bilirubin levels and a mild increase in the transaminases in 
the course of prolonged parenteral nutrition administration, usually > 2 weeks. Caloric overload by 
dextrose, lipids as well as amino acids have been related to the development of parenteral nutrition 
associated cholestasis [17, 18].  
 
Initially the parenteral nutrition associated cholestasis is essentially a functional cholestasis, 
decreased bile flow, which resolves quickly if the parenteral nutrition is discontinued. At 
histopathological level one can only detect intracellular and intracanalicular cholestasis. This may 
evolve to steatosis, periportal inflammation, bile duct proliferation, fibrosis and in the end biliary 
cirrhosis.  
 
 
1.4. Liver histology of ICU jaundice 
 
Cholestasis is in fact a dynamic phenomenon of impaired bile flow, which is obviously not reflected in 
static liver biopsies. Increased abnormally located presence of bile components in the liver 
represents cholestasis. Hence, the most prominent features of ICU jaundice are hepatocellular 
bilirubinostasis, Kupffer cell hyperplasia and portal infiltrates of monocytes. Canalicular and ductular 
bilirubinostasis can also be present. Proliferation of the bile ducts, called ductular reaction, is 
supposedly driven by the inflammation in the liver. The centrolobular region is preferentially 
affected, as it hosts the P450 microsomal enzymes, while it has the lowest pO2, indicating that a 
metabolically active region vulnerable to energy failure due to ATP generation. 
 
Rarely ICU jaundice is the result of extra-hepatocytic processes. These include mechanical 
obstruction of the bile ducts and inflammation-driven narrowing of the bile ducts. In cholangitis lenta 
the small bile ducts are affected, while the large ducts are the primary focus in progressive sclerosing 
cholangitis [9]. Even the gallbladder can be caught in the cholestatic processes during critical illness 
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[19]. Biliary sludge is the presence of sediment in the gallbladder. It is commonly found in critically ill 
patients after an ICU-stay of already a few days and is diagnosed by ultrasonography [20]. Decreased 
bile flow by gallbladder dysmobility and changes in the composition of the bile are the main factors. 
Major abdominal surgery, trauma, transplantation and the administration of parenteral nutrition and 
antibiotics such as ceftriaxone have been described as risk factors for biliary sludge. Gallbladder 
sludge not necessary results in gallstones. However, it can give rise to the serious complication of 
acalculous cholecystitis. Cholangitis and acute pancreatitis are infrequently the result of gallbladder 
sludge. Usually biliary sludge resolves when the patient is improving.  
 
 
1.5. Molecular mechanisms of bile flow 
 
Hepatobiliary transport systems are responsible for the bile formation [21]. Maintenance of cell 
polarity through the presence of tight junctions and an intact cytoskeleton are necessary to create 
distinctive basolateral and apical sides of the hepatocytes, as well as to seal off the bile canaliculi. 
Secondly, hepatobiliary transporters mediate the excretory function of the liver. Biliary components 
and lipophilic endo- and exotoxins are taken up from the blood in the sinusoids at the basolateral 
side of the hepatocyte. After uptake into the hepatocyte, these components are modified and then 
conjugated in processes such as methylation, sulphatation, acetylation, glucuronidation and 
glycine/taurine/glutathione conjugation. In general, modification and conjugation are meant to lower 
the toxicity of these toxins. Finally, they are transported over the canalicular membrane into the bile 
compartment. Hence, the normal vector of transport goes from the basolateral -blood- compartment 
to the apical -canalicular- compartment.  
 
The export of these toxins carried out by the ATP-binding cassette (ABC) transporters at the 
basolateral and apical membrane of the hepatocyte. Hepatic uptake of bile acids at the basolateral 
membrane is mediated by the sodium-dependent bile salt transporter Na+/taurocholate co-
transporting polypeptide (NTCP) and several organic anion transporters (OATPs) [22, 23]. These 
transporters are not specific for bilirubin and bile acids only. NTCP actively co-transports bile acids 
and Na+, using the Na+ gradient, created by the Na+/K+ ATPase. The driving force for the OATPs is 
anion exchange, instead of the Na+ gradient. Amphipathic organic anions, such as bile salts and their 
conjugates, hormones and xenobiotics use the OATPs, with OATP2 (OATP1B1) and OATP8 (OATP1B3) 
the most important members.  
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Unconjugated bilirubin is supposed to either passively diffuse through the basolateral membrane due 
to its highly hydrophobic character or to be transported by OATP2.  
Inside the hepatocyte the bile acids, bilirubin and toxins are modified and conjugated and require an 
intact cytoskeleton to be intracellularly transported to the apical membrane. Transporting them 
across the apical membrane in the canaliculi happens against a steep concentration gradient. This 
requires a lot of energy as ATP use. The equivalent of basolateral NTCP is the bile salt export pump 
(BSEP) at the apical site. In contrast to the basolateral transporters, BSEP’s substrate specificity is 
confined to the monovalent bile salts. As apical transport is the rate-limiting factor, BSEP basically 
drives the bile salt dependent bile flow.  
 
The other transporters at the canalicular membrane are from the multidrug resistance protein or 
from the multidrug resistance associated protein family. Multidrug resistance protein 1 (MDR1) is 
only expressed in the apical membrane but also in the cholangiocytes, kidney and the intestines, to 
facilitate toxin elimination [24]. The canalicular multidrug resistance protein 3 (MDR 3) transporters 
translocate phosphatidylcholine from the inner to the outer leaflet of the apical membrane. 
Therefore it is often called the phosphatidylcholine flippase. Phosphatidylcholine and bile salts 
aggregate in the micelles of the bile to protect the biliary epithelium from the detergent properties 
of the bile acids. The multidrug resistance associated protein 2 (MRP2) transports divalent bile acids 
and a wide range of amphipathic conjugates, such as bilirubin diglucuronide and glutathione. MRP2 is 
also localized in the kidney and the intestines.  
 
However, there are also efflux pumps located at the basolateral membrane. Multidrug resistance 
associated protein 3 (MRP3) and multidrug resistance associated protein 4 (MRP4) are the most 
important ones. They are normally expressed in hepatocytes at very low levels. During cholestasis 
and ‘toxic stress’ to the hepatocytes they are upregulated [25, 26]. When they are upregulated, bile 
acid transport is reversed back into the plasma [27]. Organic solute transporters (OSTalpha and 
OSTbeta) are similarly upregulated during cholestasis. Both MRP3/4 and OST transport bile acids and 
conjugated sterols, such as steroids and prostaglandins.  
 
Hepatobiliary transport is heavily regulated at the transcriptional and post-transcriptional level. 
Nuclear receptors (NRs) and transcription factors that are predominantly expressed in the liver, such 
hepatocyte nuclear factors HNF1, HNF3 and HNF4 [28]. In physiological conditions farnesoid X 
receptor (FXR) is the ‘bile acid sensor’. FXR activation is known to lead to repression of basolateral BA 
uptake (NTCP, OATP1B1) and BA synthesis. FXR activation at the same time induces canalicular 
(BSEP, MRP2, MDR3) and basolateral efflux systems (organic solute transporter alpha/beta) [29]. 
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Recently it has become clear that the NRs vitamin D receptor (VDR), pregnane X receptor (PXR) and 
constitutive androstane receptor (CAR) have significant regulatory roles in BA metabolism and/or 
transport. PXR and CAR also function as master regulators of the defence against xenobiotic (e.g. 
drugs) and endobiotic toxicity. Most of the transporters are also under post-transcriptional 
regulation. Insertion and retrieval of transporter proteins from vesicles (vesicular targeting and 
redistribution), post-translational modifications such as phosphorylation and glycosylation are just a 
few examples. Hence, it is clear that measuring gene or even protein expression of the bile acid 
transporters will always remain a surrogate marker for their in vivo activity. In fact, the relationship 
between transporter activity and bile flow is also under the influence of many other factors.  
 
 
1.6. Management of ICU jaundice and gallbladder sludge during 
critical illness 
 
The cornerstone in the management of ICU jaundice and gallbladder sludge during critical illness is 
their prompt diagnosis [9, 30]. Serum liver function tests and ultrasonography are the essential 
diagnostic tools. Adequate management of the hemodynamic status and infections are the basic but 
aspecific steps in the treatment. Starting enteral nutrition, when possible, and intensive insulin 
therapy to maintain normoglycemia may help to prevent or resolve ICU jaundice and gallbladder 
sludge [20]. The administration of ursodeoxycholic acid, a highly hydrophilic bile acid, has been 
shown to improve biochemical cholestasis and clinical parameters in cholestatic syndromes such as 
primary biliary cirrhosis. However, its use in ICU jaundice is not supported by strong clinical evidence. 
The administration of corticosteroids can be considered in acute drug-induced or inflammation-
induced cholestasis. But data are lacking for the use of steroids to tackle ICU jaundice. 
 
 
1.7. Rationale for the study of the role of parenteral nutrition during 
critical illness 
 
Sepsis and critical illness have been associated with the development of ICU jaundice and cholestasis. 
Similarly, prolonged administration of parenteral nutrition is linked to the cholestatic disorders. 
Although, the use of parenteral nutrition has been shown to aggravate the risk for ICU jaundice 
during critical illness in observational studies, causality has never been demonstrated. It is well 
known that it is much harder to reach the caloric goals with enteral nutrition when the patient is 
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more severely ill. Hence, ICU jaundice may just reflect severity of illness. The causal relationship 
between parenteral nutrition and ICU jaundice and cholestasis can only be proven in interventional 
studies. Therefore, a randomized controlled trial in human subjects and animal studies with differing 
parenteral nutrition schemes are needed to assess the impact of parenteral nutrition on the clinical 
outcome and on changes in bile acid transporter expression.  
Changes in the biochemical profile, as well as in the molecular basis of cholestasis, need to be 
assessed in light of the difference between acute and prolonged critical illness. Overt conjugated 
hyperbilirubinemia in the prolonged phase of critical illness may not be the same as a mild increase 
of circulating bilirubin during the acute phase of critical illness. The cholestatic response may either 
be heralding nearing death, or a maladaptive response to critical illness, or a protective response in 
acute as well prolonged phase of critical illness.  
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Chapter 2: Aim and study objectives 
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2.1. Aim 
 
The aim of this thesis project is the assessment of cholestatic changes at biochemical and molecular 
level during critical illness. Their influence on outcome during critical illness will be evaluated in the 
context of a metabolic challenge, either caloric restriction or full nutritional support by parenteral 
nutrition. 
 
2.2. General hypothesis 
 
The central hypothesis of this doctoral research project states that ‘cholestasis’ in the early phase of 
critical illness is brought about by changes in bile acid synthesis and transport and is a protective 
response of the liver. Parenteral nutrition can modify this protective cholestatic response.  
 
2.3. Specific study objectives 
 
This hypothesis was tested by means of the following specific study objectives: 
 
(1) To unravel the mechanisms behind the cholestasis during critical illness the expression of bile 
acid transporters and synthesis enzymes, together with the regulating network of nuclear 
receptors will be analyzed in liver biopsies of critically ill patients and control patients 
undergoing major abdominal surgery. 
 
(2) The effect of caloric restriction or, on the other hand, nutritional support by parenteral 
nutrition on serum markers of cholestasis and the expression of bile acid transporters and 
synthesis enzymes, together with their regulating network of nuclear receptors will be 
studied in a validated rabbit model of critical illness. 
 
(3) In a post-hoc analysis of a large randomized controlled trial in critically ill patients the effect 
of either caloric restriction or nutritional support by parenteral nutrition on the development 
of biochemical cholestasis and gallbladder sludge during the first week of critical illness will 
be examined. 
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Chapter 3:  
Critical illness evokes elevated circulating bile acids related to altered hepatic 
transporter and nuclear receptor expression 
 
 
This chapter has been published as: 
Vanwijngaerden Y-M, Wauters J, Langouche L, Vander Perre S, Liddle Ch, Coulter S, Vander Borght S, 
Roskams T, Wilmer A, Van den Berghe G, Mesotten D. Critical illness evokes elevated circulating bile 
acids related to altered hepatic transporter and nuclear receptor expression. Hepatology. 2011 
Nov;54(5):1741-52. 
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3.1. Abstract  
 
Hyperbilirubinemia is common during critical illness and is associated with adverse outcome. 
Whether hyperbilirubinemia reflects ICU cholestasis is unclear. Therefore, the aim of this study was 
to analyze hyperbilirubinemia in conjunction with serum bile acids (BAs) and the key steps in BA 
synthesis, transport and regulation by nuclear receptors (NRs).  
 
Serum BA and bilirubin levels were determined in 130 ICU and 20 control patients. In liver biopsies 
mRNA expression of BA synthesis enzymes, BA transporters and NRs was assessed. In a subset (40 
ICU/10 controls) immunohistochemical staining of the transporters and receptors together with a 
histological evaluation of cholestasis was performed. 
BA levels were much more elevated than bilirubin in ICU patients. Conjugated cholic acid (CA) and 
chenodeoxycholic acid (CDCA) were elevated, with an increased CA/CDCA ratio. Unconjugated BA did 
not differ between controls and patients.  
 
Despite elevated serum BA levels, CYP7A1 protein, the rate-limiting enzyme in BA synthesis, was not 
lowered in ICU patients. Also, protein expression of the apical bile salt export pump (BSEP) was 
decreased, while multidrug resistance-associated protein (MRP) 3 was strongly increased at the 
basolateral side. This reversal of BA transport towards the sinusoidal blood compartment is in line 
with the increased serum conjugated BA levels. Immunostaining showed marked downregulation of 
nuclear farnesoid X receptor (FXR), retinoid x receptor alpha (RXRα), constitutive androstane 
receptor (CAR) and pregnane x receptor (PXR) nuclear protein levels. 
 
Conclusion: Failure to inhibit BA synthesis, upregulate canalicular BA export and localize pivotal NR in 
the hepatocytic nuclei may indicate dysfunctional feedback regulation by increased BA levels. 
Alternatively, critical illness may result in maintained BA-synthesis (CYP7A1), reversal of normal BA 
transport (BSEP/MRP3) and inhibition of the BA sensor (FXR/RXRα) to increase serum BA levels. 
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3.2. Introduction 
 
Almost 20% of the intensive care unit (ICU) patients develop ICU jaundice or cholestasis, which has 
been linked to an increased risk of mortality and length of stay [1, 2]. Currently there is no consensus 
on the definition of cholestasis during critical illness. Most commonly, routine laboratory 
measurements of bilirubin and alkaline phosphatase (ALP) / gamma-glutamyl transpeptidase (GGT) 
with different cut-offs are used [2-4]. Therefore, in clinical practice ICU cholestasis is the equivalent 
of conjugated hyperbilirubinemia. As a causal link between hyperbilirubinemia and worse outcome is 
missing, it may even be a biochemical epiphenomenon. Additionally, the reliability of 
hyperbilirubinemia as a marker of cholestasis in critically ill patients may be questionable, since there 
are many factors that can influence the levels of bilirubin. The weakness of bilirubin as marker of 
cholestasis during critical illness and the absent mechanistic underpinning of ICU cholestasis were the 
main driver for this study. 
 
To date, the behavior and impact of bile acids (BAs) during ICU jaundice has been neglected, despite 
their crucial role in bile formation [5], lipid/cholesterol metabolism and energy and glucose 
homeostasis [6]. Also studies on the BA transporters and their regulatory network of nuclear 
receptors (NRs) has so far been focused on either chronic cholestatic liver disorders, such as primary 
biliary cirrhosis or familial intrahepatic cholestasis [7] or on acute animal models of sepsis [8]. 
Endotoxin-induced pro-inflammatory cytokines lead to reduced Na+/taurocholate co-transporting 
polypeptide (NTCP) and organic anion transporting polypeptide (OATP) expression [8]. Expression of 
the canalicular efflux pumps, bile salt export pump (BSEP) and multidrug resistance-associated 
protein (MRP) 2 is reduced during rat endotoxemia, while multidrug resistance protein (MDR) 1 
expression is increased [8]. MRP3 and MRP4, inducible basolateral efflux pumps, are strongly 
upregulated and may serve as an alternative escape route for cytotoxic compounds from 
hepatocytes into sinusoidal blood [7]. 
 
BA metabolism and transporter function is regulated by a complex network of NRs, together with 
their co-activators and co-repressors [9]. In physiological conditions farnesoid X receptor (FXR) is the 
‘bile acid sensor’. FXR activation is known to lead to repression of basolateral BA uptake (NTCP, 
OATP1B1) and BA-synthesis. FXR activation at the same time induces canalicular (BSEP, MRP2, 
MDR3) and basolateral efflux systems (organic solute transporter alpha/beta). Recently it has 
become clear that the NRs vitamin D receptor (VDR), pregnane X receptor (PXR) and constitutive 
androstane receptor (CAR) have significant regulatory roles in BA metabolism and/or transport [9].  
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The aim of this study was to examine a large cohort of critically ill patients to gain mechanistic 
insights into ICU jaundice, with a focus on BAs, hepatocytic transporters involved in bile production 
as well as their regulating NRs. An understanding of these mechanisms has the potential not only to 
expand our knowledge of hepatic metabolic dysfunction in the critically ill but it may also convey 
hints whether hyperbilirubinemia or increased serum BA are a biochemical epiphenomenon of a 
failing hepatobiliary system or a desired compensatory reaction during critical illness. 
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3.3. Material and methods  
 
Patients and serum analysis 
 
Post-mortem liver biopsies were taken from ICU patients (n=130), enrolled in two large randomized 
controlled trials studying the effects of intensive insulin therapy in critically ill patients. [10, 11]. All 
deaths occurred after a multidisciplinary decision to restrict therapy when further treatment was 
judged to be futile. All liver samples were harvested within minutes after death. For comparison, liver 
biopsies from 20 demographically matched patients (controls) undergoing an elective restorative 
rectal resection were obtained. All protocol and consent forms were approved by the Institutional 
Review Board of the Katholieke Universiteit Leuven. Written informed consent was obtained from all 
patients, or, when the patient was unable to give consent, from the closest family member. All liver 
biopsies were taken from liver segment IVb, snap-frozen in liquid nitrogen, and stored at -80°C until 
analysis. 
 
For all ICU patients, blood samples were taken on admission and the last day of ICU stay. Liver 
biochemistry was analyzed by routine automated laboratory assays: total bilirubin, alanine 
aminotransferase (ALT); aspartate aminotransferase (AST), GGT and ALP. Blood samples from 
controls were taken pre-operatively. Sepsis was defined according to Bone criteria as suspected or 
documented infection on the day of admission to the ICU and fulfillment of at least two of the three 
criteria for the systemic inflammatory response syndrome (receiving ventilatory support, white-cell 
count ≤ 4000 or ≥12,000 per cubic millimeter, and body temperature ≤36°C or ≥38°C) [12]. Serum 
concentrations of cytokines were quantified by a multiplexed microbead suspension enzyme-linked 
immunosorbent assay (Biosource, Carlsbad, CA) using the Luminex 100 system (Luminex Corp, 
Austin, TX) as previously published [13]. 
 
Individual serum BAs were quantified by high performance liquid chromatography-mass 
spectrometry using authentic BA standards and deuterated internal standards [14]. 
 
Gene and protein expression on liver biopsies 
 
Total RNA was isolated and quantified as previously described [15]. Commercial gene expression 
assays from Applied Biosystems were used and are listed in Supplemental table 3.1. Data are 
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expressed as fold increase relative to the mean of the control patients. Immunoblot analysis of 
CYP7A1 was performed as described in the online supplement. 
 
Histological and immunohistochemical analysis 
 
For histological and immunohistochemical analysis, liver sections from a randomly chosen subset of 
study patients (40 ICU and 10 controls) were used. Four µm-thick sections were cut from frozen 
samples and stained with hematoxylin and eosin for a general histological assessment. For evaluation 
of bilirubinostasis and ductular reaction, sections were stained by Hall’s method and for cytokeratin 7 
(CK7) (Dako, Glostrup, Denmark). For immunohistochemistry 5 µm-thick frozen sections were dried 
overnight at room temperature, fixed in acetone for 10 minutes and washed in PBS immediately 
prior to use. Sections were incubated with primary antibodies for 30 min at room temperature. The 
primary antibodies used are listed in Supplemental table 3.2. For the staining of CK7, OATP2/8, 
MRP3, MRP2, MDR1 and MDR3 the second and third step consisted of peroxidase-labelled rabbit 
anti-mouse and peroxidase-labelled swine anti-rabbit immunoglobulins (both Dako, Glostrup, 
Denmark). Secondary and tertiary antibodies were diluted (1:50 and 1:100, respectively) in PBS (pH 
7.2) containing 10 % normal human serum. For the staining of BSEP, the slides were incubated with 
an anti-rabbit peroxidase conjugated Envision antibody (Dako) and subsequently incubated with a 
goat peroxidase anti-peroxidase complex (goat PAP complex; Dako). For NTCP staining a protein 
block was performed prior to the application of the primary antibody to counteract the strong 
sinusoidal staining and the secondary step consisted of peroxidase-labelled swine anti-rabbit IgG 
(dilution 1:100; Dako), followed by peroxidase-labelled rabbit anti-swine IgG (dilution 1:100; Dako). 
 
For the staining of the NRs sections were incubated with the primary antibody for 30 minutes at 
room temperature and subsequently incubated for 30 min at room temperature with anti-mouse 
peroxidase-conjugated Envision antibody (Dako). All incubations were performed for 30 min at room 
temperature and followed by a wash in 3 changes of PBS for 5 min. 
 
For all immunohistochemical stainings, 3-amino-9-ethylcarbazol (AEC) in 0.01% H2O2 was used as 
substrate-chromogen. The sections were counterstained with hematoxylin. Negative controls 
consisted of omission of the primary antibody and were consistently negative. To ensure uniform 
handling of samples, all sections were processed simultaneously. All immunohistochemical stained 
slides were evaluated for staining patterns and intensities by four observers (TR, YV, JW and LL). 
Histological changes i.e. portal inflammation; hepatocellular, canalicular and ductular bilirubinostasis; 
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ductular reaction; steatosis and centrolobular necrosis were graded using a semi-quantitative scoring 
system. BA transporter expression was semi-quantitatively graded as compared to what was deemed 
normal by the pathologist. For the assessment of NRs, intensity of nuclear localized staining was 
scored. 
 
Statistical analysis 
 
Statistical analysis was performed using Statview 5.0.1 (SAS Institute, Cary, NC). All quantitative 
values were assessed for normality. Values with normal distribution, and those that were normalized 
after logarithmic transformation, are represented as mean  standard error of the mean (SEM) and 
were compared using the unpaired Student’s t-test. The non-normally distributed data were 
represented as medians and interquartile range (IQR) (1st-3rd) and compared by the non-parametric 
Mann-Whitney U test. Nominal and ordinal variables (expressed as numbers and percentages) were 
compared by Fisher’s exact test. Correlations between variables were calculated using either 
Pearson’s or Spearman’s rank correlation test. For all comparisons a p-value less than 0.05 was 
deemed significant. 
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Table 3.1 Baseline characteristics of control and ICU patients 
 
 
Baseline characteristics for all control and ICU patients. Represented p-values are calculated for the 
comparison between ICU and control patients. All data are represented as mean ± SEM or median with IQR 
(25
th
-75
th
 percentiles) as appropriate. 
  
 Control (n=20) ICU (n=130) p-value 
Gender (% male)  65 64 0.9 
Age (years)  68 ± 3 68 ± 1 0.7 
BMI (kg/m
2
)  25.1 ± 0,6 24.9 ± 0.4 0.4 
LOS ICU (days)   10 (6-21)  
APACHE II (score)  19 (12-27)  
Diagnostic Group (n,%)    
Cardiovascular disease / high-risk cardiac or 
complicated vascular surgery 
 33 (25)  
Respiratory disease / complicated pulmonary or 
esophageal surgery 
 42 (32)  
Gastrointestinal or hepatic disease / complicated 
abdominal surgery 
 16 (12)  
Neurology / neurosurgery  14 (11)  
Hematology / oncology  9 (7)  
Solid organ transplant  1 (<1)  
Polytrauma  3 (2)  
Renal / metabolic  2 (2)  
Other   10 (8)  
Sepsis (n, %)  65 (50)  
Serum markers on admission    
CRP (mg/L)  131 (61-192)  
ALT (IU/L)  29 (15-59)  
AST (IU/L)  48 (27-95)  
Total Bilirubin (mg/dL)  1.18 (0.63-2.41)  
GGT (IU/L)  40 (25-78)  
ALP (IU/L)  175 (125-258)  
Serum markers on day of biopsy    
CRP (mg/L) 7 (4-28) 150 (88-219) <0.0001 
Cytokines    
TNFα (pg/mL)  5160 (8-23825)   
IL-1β (pg/mL)  6750 (18-19963)  
IL-6 (pg/mL)  92910 (535-269918)  
ALT (IU/L) 15 (14-18) 46 (26-125) 0.0002 
AST (IU/L) 18 (15-21) 62 (36-157) <0.0001 
Total Bilirubin (mg/dL) 0.37 (0.29-0.46) 2.89 (1.08-8.87) <0.0001 
GGT (IU/L) 25 (20-46) 75 (41-204) 0.004 
ALP (IU/L) 220 (180-242) 350 (209-689) 0.02 
Total bile acids (µM) 0.62 (0.42-0.92) 6.88 (3.12-17.71) <0.0001 
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3.4. Results 
 
Biochemistry in ICU and control patients 
 
Baseline characteristics of ICU (n=130) and control (n=20) patients are described in table 3.1. The 
total ICU population, as well as the subset used for immunohistochemical analysis, was matched with 
control patients for gender, age and body mass index (Supplemental table 3.3). 
 
Serum total bilirubin on the last day of ICU stay was 8-fold higher in ICU patients than in controls 
(Table 3.1) and the hyperbilirubinemia was predominantly conjugated. Compared to controls, serum 
ALP and GGT levels in ICU patients were 1.6- and 3-fold higher respectively (Table 3.1). In parallel, 
serum total BAs were 11-fold higher (p<0.0001) in ICU patients (Table 3.1), this increase being mainly 
attributable to conjugated BAs (Table 3.2). There was no effect of tight glycemic control on 
circulating bilirubin or BA levels. There was an increase in conjugation percentage for the primary BA 
cholic acid (CA) (98.3% in patients vs 55.6% in controls) and chenodeoxycholic acid (CDCA) (95.9% in 
patients vs 37.5% in controls) (p<0.0001). Serum levels of glycocholic acid (G-CA) were on average 
83-fold increased in ICU versus control patients, while glycochenodeoxycholic acid (G-CDCA) was 34-
fold higher in the critically ill population. Taurocholic acid (T-CA) was 22-fold and 
taurochenodeoxycholic acid (T-CDCA) was 39-fold increased in critical illness. Serum levels of the 
unconjugated BAs CA, CDCA and deoxycholic acid (DCA) did not differ between the two populations. 
The ratio of unconjugated CA/CDCA (0.5 in patients vs 0.3 in controls, p=0.003) as well 
glycoconjugated CA/CDCA (1.1 in patients vs 0.4 in controls, p<0.0001) was higher in critically ill 
patients. After logarithmic transformation, serum levels of total bilirubin correlated strongly with G-
CA, G-CDCA, T-CA and T-CDCA on the day of biopsy as shown in figure 3.1. Changes in serum markers 
of cholestasis and bilirubinostasis in the subset of ICU patients used for immunohistochemical 
analysis were similar to those seen in the entire ICU population used for mRNA analysis (data not 
shown). 
 
Serum levels for TNFα, IL-1β, IL-6 are shown in table 3.1. In over 80% of the ICU patients levels of 
IFNγ, IL-2, IL-4 and IL-5 were undetectable, while in the control patients all measured cytokines were 
below the assay detection limits.  
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Figure 3.1 Correlation between serum levels of bile acids and total bilirubin 
 
Correlation between serum levels of conjugated primary bile acids G-CA, G-CDCA, T-CA and T-CDCA and total 
bilirubin for ICU and control patients on day of biopsy. ( ) Open dots represent values below detection limit. 
 
Table 3.2  Serum levels of bile acids for control and ICU patients 
 
Bile acid (µM) Control (n=20) ICU (n=130) p-value 
CA  0.04 (0.01 - 0.05) 0.05 (0.02 – 0.15) 0.06 
CDCA  0.10 (0.09 – 0.15) 0.09 (0.05 – 0.18) 0.5 
DCA  0.05 (0.05 – 0.08) 0.05 (0.05 – 0.13) 0.4 
LCA* 0.04 (0.04 – 0.04) 0.04 (0.04 - 0.04) 0.2 
UDCA*  0.01 (0.01 – 0.07) 0.01 (0.01 – 0.01) 0.2 
G-CA  0.03 (0.03 – 0.09) 2.49 (0.68 – 7.25) <0.0001 
G-CDCA  0.05 (0.05 – 0.34) 1.70 (0.82 – 5.82) <0.0001 
G-DCA*  0.01 (0.01 – 0.01) 0.01 (0.01 – 0.14) 0.05 
G-UDCA*  0.02 (0.02 – 0.02) 0.02 (0.02 – 0.13) 0.1 
T-CA  0.02 (0.02 – 0.02) 0.43 (0.13 – 1.31) <0.0001 
T-CDCA  0.01 (0.01 – 0.01) 0.39 (0.01 – 1.16 <0.0001 
T-DCA* 0.03 (0.03 – 0.03) 0.03 (0.03 – 0.03) 0.1 
T-UDCA* 0.01 (0.01 – 0.01) 0.01 (0.01 – 0.01) 0.7 
T-LCA* 0.01 (0.01 – 0.01) 0.01 (0.01 – 0.01) 0.9 
 
Serum levels of bile acids for control and ICU patients on day of biopsy. Levels are expressed in µM and are 
represented as median with IQR (25
th
-75
th
 percentiles). (*) more than 60% of the samples were below the 
detection limit.  
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Histological characteristics of cholestasis in ICU and control patients 
 
Liver histology and immunohistochemical staining were performed in a random subset of 40 ICU 
patients and 10 controls (Table 3.3). The majority of the ICU biopsies exhibited typical histological 
features of intra-hepatic cholestasis (Figure 3.2). In 82% of the liver biopsies from the ICU patients 
hepatocellular and canalicular bilirubinostasis was present, while in 34% ductular bilirubinostasis also 
was present. This was absent in the control biopsies. A mild ductular reaction was seen in 20% of 
controls compared to ICU biopsies that showed a mild (37%) to severe (47%) ductular reaction. In 
42% of ICU patients signs of cholangiolitis were observed. In contrast, the presence of portal 
inflammation did not differ between ICU patients and controls.  
 
Morphological signs of cholestasis were linked with biochemical markers of cholestasis measured on 
the day of the biopsy. The degree of bilirubinostasis correlated with serum levels of total bilirubin 
(ρ=0.816, p<0.0001), ALP (ρ=0.472, p=0.008), GGT (ρ=0.495, p=0.008), G-CA (ρ=0.775, p<0.0001), G-
CDCA (ρ=0.726, p<0.0001), T-CA (ρ=0.739, p<0.0001) and T-CDCA (ρ=0.566, p=0.0001). The presence 
of ductular reaction also correlated with the serum levels of total bilirubin (ρ=0.709, p<0.0001), ALP 
(ρ=0.539, p=0.002), GGT (ρ=0.483, p=0.009), G-CA (ρ=0.591, p<0.0001), G-CDCA (ρ=0.598, p<0.0001), 
T-CA (ρ=0.696, p<0.0001) and T-CDCA (ρ=0.658, p<0.0001). 
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Figure 3.2  Representative liver sections for bilirubinostasis and ductular reaction 
 
Left panel: Control patients. Right panel: ICU patients. A: Control patient with normal liver tissue with normal 
portal tract (PT) and no signs of cholestasis (left panel). Extensive cholestasis with hepatocellular (arrowhead), 
canalicular (short arrow) and ductular (long arrow) bilirubinostasis. PT with a dilated ductulus filled with a bile 
plug (right panel + small frame in the left lower corner) B: Normal CK7 staining of intralobular bile duct (left 
panel). Increased CK7 staining with ductular proliferation at the interface of the portal tract and the liver 
parenchyma (right panel).  
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Bile Acid synthetic enzymes in prolonged critically ill patients 
 
Hepatic mRNA expression of CYP7A1, the rate-limiting step in BA synthesis was decreased by 94% in 
ICU patients compared to controls (p<0.0001), but CYP7A1 protein expression did not differ between 
the two groups. However, within the ICU group an inverse correlation between CYP7A1 protein and 
the serum levels of total BAs was observed. (r=-0.347, p=0.0001). In contrast, mRNA expression of 
CYP8B1, an enzyme involved in the synthesis of CA, was increased by 240% (p<0.0001). 
 
Bile salt transporters in prolonged critically ill patients 
 
In ICU patients, mRNA expression of the basolateral uptake transporters NTCP, OATP2 and OATP8 
was downregulated compared with controls (Figure 3.3), but NTCP immunohistochemical staining did 
not differ between groups (Table 3.3). OATP2/8 staining had a clear intensity gradient from 
centrolobular to periportal regions in control patients. In 11/34 ICU patients a more uniform and 
extended staining with gradient fading was observed (Table 3.3). 
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Table 3.3  General histology, immunohistochemistry of hepatobiliary transporters and nuclear 
receptors of liver sections of control and ICU patients 
 
IHC score Control (n=10) ICU (n=40) p-value 
G
en
e
ra
l 
Bilirubinostasis   <0.0001 
0 10 (100) 7 (18)  
1 0 (0) 17 (45)  
2 0 (0) 14 (37)  
Ductular reaction   0.0009 
0 8 (80) 6 (16)  
1 2 (20) 14 (37)  
2 0 (0) 11 (29)  
3 0 (0) 7 (18)  
Portal inflammation   0.6 
0 4 (40) 11 (29)  
1 6 (60) 24 (63)  
2 0 (0) 3 (8)  
H
ep
at
o
b
ili
ar
y 
tr
an
sp
o
rt
er
s 
NTCP   0.7 
-2 0 (0) 4(11)  
-1 3 (33) 11 (29)  
0 3 (33) 8 (22)  
1 3 (33) 11 (30)  
2 0 (0) 3 (8)  
OATP2/8   0.07 
-1 0 (0) 5 (15)  
0 7 (78) 11 (32)  
1 2 (22) 11 (32)  
2 0 (0) 7 (21)  
MRP3   <0.0001 
0 6 (67) 3 (8)  
1 3 (33) 9 (24)  
2 0 (0) 26 (68)  
BSEP   0.02 
-2 0 (0) 11 (28)  
-1 2 (22) 16 (42)  
0 7 (78) 11 (28)  
MRP2   0.02 
0 8 ( 80) 13 (34)  
1 2 (20) 10 (26)  
2 0 (0) 15 (40)  
MDR1   0.05 
0 9 (90) 18 (47)  
1 1 (10) 13 (34)  
2 0 (0) 7 (18)  
MDR3   0.0002 
0 9 (90) 8 (21)  
1 1 (10) 14 (37)  
2 0 (0) 16 (42)  
  
 31  
Table 3.3  General histology, immunohistochemistry of hepatobiliary transporters and nuclear 
receptors of liver sections of control and ICU patients (Continued.) 
 
IHC score Control (n=10) ICU (n=40) p-value 
N
u
cl
ea
r 
re
ce
p
to
rs
 
CAR   <0.0001 
0 0 (0) 3 (8)  
1 0 (0) 18 (47)  
2 1 (11) 12 (32)  
3 8 (89) 5 (13)  
VDR   0.2 
0 1 (11) 13 (33)  
1 6 (67) 13 (33)  
2 2 (22) 14 (35)  
FXR   0.04 
0 1 (10) 7 (18)  
1 2 (20) 12 (31)  
2 2 (20) 16 (41)  
3 5 (50) 4 (10)  
RXRα   0.0004 
0 1 (10) 3 (8)  
1 0 (0) 14 (36)  
2 0 (0) 14 (36)  
3 9 (90) 8 (21)  
PXR   0.01 
0 1 (10) 14 (35)  
1 0 (0) 12 (30)  
2 4 (40) 9 (23)  
3 5 (50) 5 (13)  
 
Histological assessment (for bilirubinostasis, ductular reaction and portal inflammation), immunohistochemical 
assessment of the expression of hepatobiliary transporters and nuclear receptors of liver sections of 40 ICU and 
10 control patients. Data are represented as numbers and percentages (between brackets). Represented p-
values are calculated for the comparison ICU versus control patients.  
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Figure 3.3  mRNA levels of hepatobiliary transporters and nuclear receptors in control and ICU 
patients 
 
Upper panel: mRNA levels of hepatic basolateral influx pumps (NTCP, OATP2, OATP8), basolateral efflux 
transporters (MRP3, MRP4) and canalicular efflux pumps (BSEP, MRP2, MDR1, MDR3) of 130 ICU patients. 
Lower panel: mRNA levels of hepatic nuclear receptors (FXR, VDR, CAR, PXR, RXRA and SHP) of 130 ICU 
patients. mRNA levels are expressed relative to the mRNA expression of the housekeeping gene HPRT and 
relative to 20 control patients. Data are represented as median with IQR (25
th
-75
th
 percentiles). 
 
 
In contrast, mRNA levels of MRP3 and MRP4, the basolateral efflux transporters, were strongly 
upregulated. Immunohistochemistry confirmed a marked upregulation of MRP3 staining in ICU 
patients compared to control subjects (p<0.0001) (Table 3.3). Moreover, while controls only 
exhibited basolateral MRP3 staining in the centrolobular zone of the liver lobule, ICU patients 
showed a strong panlobular honeycomb staining pattern (Figure 3.4). For MRP3, mRNA and protein 
levels were in agreement (ρ=0.432, p=0.004). Moreover, MRP3 expression correlated positively with 
the degree of bilirubinostasis both at mRNA level (ρ=0.529, p=0.0003) and at protein level (ρ=0.591, 
p<0.0001). There was also a strong correlation between the MRP3 protein levels and biochemical 
markers of cholestatic liver dysfunction i.e. the serum levels of total bilirubin (ρ=0.625, p=0.0003), 
GGT (ρ=0.519, p=0.005), ALP (ρ=0.551, p=0.002), G-CA (ρ=0.494, p=0.0008) and G-CDCA (ρ=0.484, 
p=0.001). Due to technical limitations, we were not able to stain for MRP4. 
mRNA expression of the canalicular efflux pumps BSEP, MRP2, MDR1 and MDR3 was significantly 
higher in ICU patients compared with control patients (Figure 3.3). In contrast to the increased mRNA 
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expression, protein expression of BSEP was downregulated (Table 3.3). The normal regular BSEP 
immunohistochemical staining pattern became irregular and discontinuity was observed in 
cholestatic zones. Severely cholestatic areas had no discernable immunostaining. In concert with the 
mRNA expression, MRP2 immunostaining was upregulated in ICU patients in comparison with 
controls (p=0.02) and correlated well with the degree of bilirubinostasis (ρ=0.512, p=0.0004), 
ductular reaction (ρ=0.433, p=0.003) and the serum levels of total bilirubin (ρ=0.502, p=0.003). MDR1 
and MDR3 staining was also upregulated. At the canalicular domain of the hepatocytes, a fine linear 
MDR3 pattern, seen in control subjects, evolved towards a strong double strand pattern of staining 
around multiple dilated canaliculi in ICU patients (Figure 3.4). This is indicative of a very strong 
upregulation of MDR3 protein. Similar to MRP3, MDR3 protein levels correlated with the degree of 
bilirubinostasis seen on the liver sections (ρ=0.569, p<0.0001) and serum levels of total bilirubin 
(ρ=0.745, p<0.0001), GGT (ρ=0.402, p=0.03), ALP (ρ=0.437, p=0.01), G-CA (ρ=0.639, p<0.0001) and G-
CDCA (ρ=0.548, p=0.0002) MDR1 protein staining showed a similar upregulation as MDR3 staining 
(p=0.05). 
 
 
 
Figure 3.4  Representative liver sections for MRP3, MDR3 
 
Left panel: Control patients. Right panel: ICU patients. A: Normal basolateral MRP3 staining showing clear 
centrolobular and midzonal activity (left panel). Markedly upregulated panlobular honeycomb MRP3 staining 
pattern. (right panel) B: Normal pattern of a fine canalicular linear MDR3 staining (left panel). Strong double 
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stranded pattern of MDR3 staining around multiple dilated canaliculi (right panel). (Definitions of 
abbreviations: MRP Multidrug resistance-associated protein, MDR multidrug resistance protein, CV 
Centrolobular vene, PT Portal tract) 
 
 
Nuclear receptors in prolonged critically ill patients 
 
In ICU patients, mRNA expression of the NRs FXR, VDR, PXR and RXRα was upregulated in comparison 
with control subjects. mRNA expression of CAR and SHP did not differ between groups. (Figure 3.3). 
In contrast to the increased mRNA expression, FXR, PXR and RXRα immunostaining in the nuclei was 
effectively absent in ICU patients while being clearly visible in controls (Table 3.3 and Figure 3.5). VDR 
protein expression did not differ between ICU and control patients. 
 
Nuclear CAR staining was clearly decreased in ICU patients. Control subjects showed both 
cytoplasmic and intense nuclear staining, with a clear intensity gradient from periportal to 
centrolobular regions, whereas ICU patients only showed discrete positive cytoplasmic staining and a 
marked reduction in nuclear staining (Figure 3.5).  
 
Overall there was no correlation between mRNA and protein levels for all NRs. In contrast, nuclear 
staining correlated inversely with histological and biochemical cholestatic parameters. For example, 
patients with lowest levels of nuclear CAR and RXRα staining, demonstrated the most severe 
bilirubinostasis. Serum levels of total bilirubin on the day of biopsy inversely correlated with the 
nuclear immunolocalization of CAR (ρ=-0.589, p<0.0006), FXR (ρ=-0.416, p<0.01) and RXRα (ρ=-0.553, 
p<0.001). RXRα staining also correlated well with BSEP apical protein visualization (ρ=0.581, 
p<0.0001). 
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Figure 3.5  Representative liver sections for FXR, CAR and RXRα 
 
Left panel: Control patients. Right panel: ICU patients. Normal liver with nuclear FXR (A), CAR (B) and RXRα (C) 
immunostaining clearly present in controls (left panel). Strongly decreased FXR (A), CAR (B) and RXRα (C) 
nuclear immunostaining in ICU patients (right panel). 
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3.5. Discussion 
 
This study of post-mortem liver biopsies in conjunction with pre-agonal serum analyses found that 
BA levels are much more increased during critical illness than the bilirubin concentrations. Critical 
illness was also associated with maintained CYP7A1 levels, decreased apical BSEP protein, increased 
basolateral MRP3 protein expression. Nuclear localization of FXR and its heterodimeric partner RXRα 
was diminished in critically ill patients. 
 
While bilirubin levels increased 8-fold during critical illness, the larger increase in circulating total BAs 
mainly consisted of glycine and taurine conjugates of CA and CDCA. Unconjugated CA and CDCA did 
not differ from controls. This indicates that the hepatocytes are able to conjugate potentially toxic 
BAs, either de novo synthesized or entero-hepatically recirculated. It also suggests that the transport 
of the conjugated BA towards the apical bile canaliculi is strongly shifted to the blood. The ratio of CA 
to CDCA was also increased in critically ill patients, consistent with the increased expression of 
hepatic CYP8B1 mRNA. This shift may represent a reduction in FXR-mediated FGF19 production by 
small bowel enterocytes due to reduced BAs being excreted into the gut, as FGF19 has recently been 
recognized to repress CYP8B1 in mice [16].  
 
Despite the strongly elevated serum BA levels during critical illness, CYP7A1, the rate limiting step in 
de novo BAs synthesis was only repressed at the mRNA level but not at the protein level. This is in 
line with the absence of increased SHP mRNA expression in ICU patients, which mediates BA 
repression of CYP7A1 [17]. Furthermore, FXR and its heterodimeric partner RXRα, which act in 
concert with SHP to suppress BA-synthesis enzymes, were absent from the hepatocytic nucleus, 
where they exert transcriptional activity through direct binding to DNA. This may imply an at least 
partial loss of the sensing of BAs and its feedback regulation of de novo BA production, in light of the 
increased circulating BAs in ICU patients. Alternatively, critical illness may induce elevated BA levels 
by suppressing the BA sensor FXR and maintaining (CYP7A1) and/or shifting (CYP8B1) BA-synthesis. 
Cytoplasmic retention of RXR has also been found in models of acute liver inflammation [18, 19] and 
advanced extrahepatic cancer [20]. In the present study other NRs relevant to BA-regulation, namely 
PXR and CAR, also did not localize to the nucleus. The lower nuclear levels of PXR and CAR may not 
only affect bile formation, but also metabolic processes in the liver, such as energy homeostasis [21].  
 
BAs, and bilirubin, are transported by the hepatocyte via the hepatobiliary transporters. In this study, 
the most prominent changes in the expression profile of the hepatic BA transporters during 
prolonged critical illness were observed in the basolateral efflux transporters MRP3 and MRP4. 
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Normally, MRP3 and MRP4 are expressed at very low levels in hepatocytes, but they become 
upregulated by inflammation and during longstanding cholestasis, presumably shifting transport of 
BAs back into sinusoidal blood for elimination by the kidneys [7]. Immunohistochemical expression of 
BSEP in the hepatocyte canalicular domain was dramatically reduced in ICU patients, especially in 
regions of bilirubinostasis, despite an increase in BSEP mRNA expression. Decreased expression of 
BSEP is a major contributor [22] to the cholestatic phenotype of the prolonged critically ill patient, as 
BAs will accumulate within the hepatocytes. In contrast to findings from chronic cholestatic disorders 
[7] and animal models of cholestasis [23] and sepsis [24], MRP2, the main canalicular bilirubin 
transporter, was upregulated during critical illness. This seems difficult to reconcile with the elevated 
serum bilirubin levels. Nevertheless, it may fit with the rather moderate increase in serum bilirubin, 
compared to the changes in serum BA concentrations. Besides, bile formation is a secretory process 
that depends on osmotically active solutes, mainly BAs. If the bile flow is hampered as a consequence 
of retained BAs, bilirubin will also be retained, essentially as a biochemical epiphenomenon. 
 
The data on changes of BA synthesis and disposition and their regulation by the NR, do not allow to 
state whether they are beneficial or a failing compensatory response. Data from hepatocyte-RXRα-
null mice indicate that these mice are protected against WY-14,643-induced liver injury by the 
upregulation of Mrp3 expression and increased efflux of BAs into blood for renal excretion [25]. FXR 
knock-out mice have a lower mortality rate and less liver injury during bile duct ligation. These FXR 
knock-out mice strongly increased Mrp4 and reduced Bsep expression [26]. However, FXR knock-out 
mice exhibit more hepatotoxicity when challenged with a cholic acid enriched diet [27]. Also, FXR 
agonists could be beneficial for patients with cholestatic liver diseases [28]. CAR knock-out mice 
show lower levels of serum and liver primary BAs than wild type mice during bile duct ligation [29]. 
Moreover, these CAR knock-out mice are resistant to acetaminophen liver toxicity [30]. Similarly, an 
increased bilirubin clearance has been demonstrated in PXR knock-out mice [31].  
 
Histopathology of ICU patient liver biopsies revealed classic changes of cholestasis, namely 
bilirubinostasis, ductular proliferation and variable inflammation. Increased levels of serum bilirubin 
and conjugated BAs correlated strongly with the microscopic signs of bilirubinostasis and ductular 
reaction. Ductular proliferation and ductular differentiation of the hepatocytes are considered part 
of an adaptive, protective response to cholestasis. Canalicular MDR3 was also upregulated in ICU 
patients. Given the key role of biliary phospholipids in protecting bile duct epithelium from the 
potentially toxic biliary content, upregulation of MDR3 might also exert a compensatory action, 
protecting the canalicular membrane and biliary epithelium. Since MRP3 correlated well with 
histological bilirubinostasis and serum bilirubin and conjugated BAs levels, MRP3 upregulation is a 
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likely compensatory reaction to cholestasis, as has been observed in animal bile duct ligation models 
of cholestasis [32]. The upregulation of MRP3 (and MRP4) provides a mechanism to limit 
hepatocellular retention of hydrophobic BAs and other potentially toxic compounds that would 
normally be destined for biliary excretion. This is in keeping with the selective increase in serum 
taurine and glycine conjugated BAs, which have been conjugated by hepatocytes and transported 
back into the circulation. MRP3 upregulation has also been shown in acute sepsis models without 
longer lasting cholestasis [33]. Unexpectedly, there was a lack of association between ICU cholestasis 
and markers of inflammation, suggesting that inflammation is not the main contributor to cholestasis 
in prolonged critical ill patients, as it does in acute sepsis or septic shock [8]. 
 
A limitation of this study is reliance of liver biopsy samples taken immediately post-mortem, which is 
an inherent confounder. However, ethically it was not possible to obtain study-programmed liver 
samples in unselected critically ill patients. Therefore, findings at the tissue level were always 
interpreted in the context of serum marker changes from the pre-agonal phase. 
 
In summary, critical illness is associated with a strong increase in serum BA levels. Maintenance of 
BA-synthesis, suppression of FXR/RXRα, with lowering of apical BSEP and elevated basolateral MRP3 
expression may either be a desired response during critical illness to raise serum BA concentrations 
or it may be a failing feed-back regulation on BA formation and disposition, caused by cholestasis, i.e. 
increased serum bilirubin and BA. 
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Supplemental data 
 
Supplemental table 3.1  Detailed list of assays used for mRNA expression analysis 
 
 
Gene name, Gene symbol, NCBI mRNA reference sequence, and assay ID of the commercial sets of PCR primers 
and probes (Applied Biosystems, Lennik, Belgium) of the different bile acid transporters and nuclear receptors 
used for real-time PCR detection. 
Gene Name Gene Symbol RefSeq Assay ID 
Solute carrier family 10 (sodium/bile acid 
cotransporter family), member 1 
SLC10A1 NM_003049.3 Hs00914889_m1 
Solute carrier organic anion transporter family, 
member 1B1 
SLCO1B1 NM_006446.4 Hs01036445_mH 
Solute carrier organic anion transporter family, 
member 1B3 
SLCO1B3 NM_019844.2 Hs00991170_m1 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 3 
ABCC3 NM_003786.2 Hs00978471_m1 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 4 
ABCC4 NM_001105515.1 Hs00988706_m1 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 11 
ABCC11 NM_003742.2 Hs00994822_m1 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 2 
ABCC2 NM_000392.3 Hs00960494_m1 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 1 
ABCB1 NM_000927.3 Hs01067800_m1 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 4 
ABCB4 NM_000443.3 Hs00983947_m1 
Nuclear receptor subfamily 1, group I, member 3 NR1I3 NM_001077469.1 Hs00901571_m1 
Nuclear receptor subfamily 1, group H, member 4 NR1H4 NM_005123.2 Hs00231968_m1 
Vitamin D (1,25- dihydroxyvitamin D3) receptor NR1I1 NM_001017535.1 Hs01045840_m1 
Retinoid X receptor, alpha RXRA NM_002957.4 Hs00172565_m1 
Nuclear receptor subfamily 1, group I, member 2 NR1I2 NM_033013.2 Hs00243666_m1 
Cytochrome P450, family 7, subfamily A, polypeptide 1 CYP7A1 NM_000780.3 Hs00167982_m1 
Cytochrome P450, family 8, subfamily B, polypeptide 1 CYP8B1 NM_004391.2 Hs00244754_s1 
Nuclear receptor subfamily 0, group B, member 2 NR0B2 NM_021969.2 Hs00222677_m1 
Hypoxanthine phosphoribosyltransferase 1 HPRT1 NM_000194.1 4310890E 
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Supplemental table 3.2 Primary antibodies used for immunohistochemistry and immunoblotting 
 
 Species Clone  Dilution Company 
CK7 Mouse OV-TL 12/30 mono 1:400 Dako 
      
NTCP Rabbit K9 poly 1:400 * 
OATP2/8 Mouse mMDQ mono 1:25 Progen Biotechnik 
MRP3 Mouse M3II-9 mono 1:10 Monosan 
BSEP Rabbit K12 poly 1:30 * 
MRP2 Mouse M2I-4 mono 1:50 Monosan 
MDR1 Mouse JSB-1 mono 1:10 Monosan 
MDR3 Mouse P3II-26 mono 1:50 Monosan 
      
CAR Mouse N4111 mono 1:20 PPMX 
FXR Mouse A9033A mono 1:50 PPMX 
VDR Mouse H4537 mono 1:201 PPMX 
RXRα Mouse K8508 mono 1:50 PPMX 
PXR Mouse H-11 mono 1:20 Santa Cruz 
      
CYP7A1 Rabbit Ab79847 poly 1:200 Abcam 
CK18 Mouse C-04 mono 1:10000 Abcam 
 
Detailed list of all primary antibodies used for immunohistochemistry and immunoblotting, their origin and 
dilution. 
(*) Kindly provided by Bruno Stieger 
(Definitions of abbreviations: CK Cytokeratin, NTCP Na
+
/taurocholate cotransporting polypeptide, OATP 
Organic anion transporting polypeptide, MRP Multidrug resistance-associated protein, BSEP Bile salt export 
pump, MDR Multidrug resistance protein, CAR Constitutive androstane receptor, FXR Farnesoid X receptor, 
VDR Vitamin D receptor, RXRα Retinoid X receptor alpha, PXR Pregnane X receptor, CYP Cytochrome P450) 
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Supplemental table 3.3 Baseline characteristics of control and ICU patients 
 
 Control (n=10) ICU (n=40) p-value 
Gender (% male)  70 78 0.9 
Age (years)  70 ± 5 70 ± 2 0.9 
BMI (kg/m
2
)  25.1 ± 0,8 24.1 ± 0.5 0.5 
LOS ICU (days)   15 (9-35)  
APACHE II (score)  17 (11-27)  
Diagnostic Group (n,%)    
Cardiovascular disease / high-risk cardiac or 
complicated vascular surgery 
 11 ’28)  
Respiratory disease / complicated pulmonary or 
esophageal surgery 
 15 (38)  
Gastrointestinal or hepatic disease / complicated 
abdominal surgery 
 5 (13)  
Neurology / neurosurgery  3 (8)  
Hematology / oncology  1 (3)  
Solid organ transplant    
Polytrauma  2 (5)  
Renal / metabolic  2 (5)  
Other   1 (3)  
Sepsis (n, %)  19 (48)  
Serum markers on admission    
CRP (mg/L)  100 (61-164)  
ALT (IU/L)  18 (11-35)  
AST (IU/L)  27 (21-57)  
Total Bilirubin (mg/dL)  0.91 (0.51-1.73)  
GGT (IU/L)  43 (27-72)  
ALP (IU/L)  183 (136-249)  
Serum markers on day of biopsy    
CRP (mg/L) 7 (4-28) 149 (73-220) <0.0001 
Cytokines    
TNFα (pg/mL)  2705 (9-18500)  
IL-1β (pg/mL)  5230 (77-20030)  
IL-6 (pg/mL)  102895 (292-254970)  
ALT (IU/L) 15 (14-18) 48 (33-73) 0.0003 
AST (IU/L) 18 (15-21) 53 (36-87) <0.0001 
Total Bilirubin (mg/dL) 0.37 (0.29-0.45) 2.01 (1.18-6.83) <0.0001 
GGT (IU/L) 25 (20-46) 106 (52-222) 0.001 
ALP (IU/L) 220 (180-242) 481 (339-692) 0.0008 
Total bile acids (µM) 0.68 (0.41-1.52) 7.16 (3.48-15.71) <0.0001 
 
Baseline characteristics for 10 control and 40 ICU patients, subset which was used for immunohistochemistry 
analysis. Represented p-values are calculated for the comparison between ICU and control patients. All data 
are represented as mean ± SEM or median with IQR (25
th
-75
th
 percentiles) as appropriate. (Definitions of 
abbreviations: ICU Intensive care unit, BMI Body mass index, LOS Length of stay, APACHE Acute physiology and 
chronic health assessment evaluation, CRP C-reactive protein, ALT Alanine aminotransferase, AST Aspartate 
aminotransferase, GGT Gamma-glutamyltranspeptidase, ALP Alkaline phosphatase, TNFα Tumor necrosis factor 
alpha, IL Interleukin). 
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MATERIAL AND METHODS - supplement 
 
Immunoblot analysis of CYP7A1 on liver biopsies 
 
Fifty mg of frozen liver tissue was homogenized with a Precellys 24 machine using ceramic beads 
(Bertin technologies, Montigny-le-Bretonneux, France) in lysis buffer containing phosphatase 
inhibitors (Halt Phosphatase Inhibitors Cocktail, Thermo Scientific, Aalst, Belgium). The protein 
content in the homogenate was determined by the Coomassie Protein Assay Reagent (Thermo Fisher 
Scientific, Aalst, Belgium). Equal amounts of homogenate proteins (20 µg) were separated by 
denaturing SDS gel electrophoresis in 10% Bis-Tris polyacrylamide gels (Bio-Rad Laboratories, 
Nazareth, Belgium) and transferred to nitrocellulose membranes (Hybond, Ammersham Biosciences). 
Membranes were incubated overnight at 4°C with CYP7A1 primary antibody (Abcam, Cambridge, UK) 
and goat anti-rabbit HRP-linked secondary antibody (Dako, Heverlee, Belgium) for 1 hour at room 
temperature. Immunoblots were developed using enhanced chemiluminescence technology 
(PerkinElmer, Vilvoorde, Belgium) and analyzed using ImageMaster Software 1D Elite (GE Healthcare 
Europe GmbH, Diegem, Belgium). Data were normalized for cytokeratin 18 (CK18 - Abcam, 
Cambridge, UK) as a loading control. 
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Chapter 4:  
Impact of parenteral nutrition versus fasting on hepatic bile acid production 
and transport in a rabbit model of prolonged critical illness 
 
 
This chapter is in press: 
Vanwijngaerden Y-M, Langouche L, Derde S, Liddle C, Coulter S, Van den Berghe G, Mesotten D. 
Impact of parenteral nutrition versus fasting on hepatic bile acid production and transport in a rabbit 
model of prolonged critical illness. Shock. 2013 Oct 1. [Epub ahead of print] 
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4.1. Abstract  
 
Introduction: Cholestatic liver dysfunction frequently occurs during critical illness. Administration of 
parenteral nutrition (PN) is thought to aggravate this. Underlying mechanisms are not clear. 
 
Methods: In a burn model of prolonged critical illness, rabbits were randomized to a nutritional 
strategy either accepting caloric deficits (Fasted, n=11) or covering caloric needs by PN (Fed, n=10). 
At baseline and after 7 days of critical illness, markers of hepatotoxicity, circulating bile acids and the 
hepatobiliary transport system were studied. 
 
Results: Fasted animals had lower circulating ALT/AST levels than fed animals at day 7. Compared to 
baseline values, fed animals displayed lower serum unconjugated cholic acid (CA) and deoxycholic 
acid (DCA) levels. Unconjugated DCA remained unaltered in fasted animals. Unconjugated lithocholic 
acid (LCA) was increased comparably in all animals, whereas hyodeoxycholic acid (HDCA) was not 
altered. In contrast, fasting induced a shift from unconjugated CA and DCA to glyco-CA and glyco-
DCA. Total bile acids did not correlate with the bile acid producing enzyme CYP7A1, but with the 
basolateral efflux transporter MRP3. Fasting increased protein expression of the basolateral (MRP3) 
and the canalicular (BSEP) transporter, whereas the canalicular efflux pump MRP2 was suppressed. 
Gene expression levels of the nuclear receptor FXR were lower with fasting and correlated inversely 
with MRP3. The heterodimer partner of FXR, RXRA, was increased with fasting and correlated 
positively with MRP3.  
 
Conclusion: During prolonged critical illness, withholding PN improved markers for hepatocyte injury 
and accentuated bile acid transport towards the blood. This suggests that the latter is an adaptive 
rather than a dysfunctional feedback to illness. 
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4.2. Introduction 
 
Cholestatic liver dysfunction frequently occurs during critical illness and is associated with poor 
outcome [1-3]. However, critical illness-related cholestatic liver dysfunction is not yet well 
characterized and even a clear definition of cholestasis during critical illness is still lacking. Previous 
work by us and others has indicated that an altered function of the hepatic bile acid transporters may 
be involved in the pathogenesis of this condition [3-7]. In liver biopsies of critically ill patients, we 
could demonstrate that the apical bile acid (salt) export pump BSEP was downregulated, whereas the 
basolateral efflux pumps MRP3 and MRP4, which reflux bile acids back to the circulation, were 
strongly upregulated. This reversal of bile acid transport to the blood was in line with increased 
circulating conjugated bile acids and correlated strongly with histopathological markers of 
bilirubinostasis and ductular reaction [6]. 
 
Critical illness is often accompanied by anorexia and a failing of gastro-intestinal function. To prevent 
caloric deficits, when enteral nutrition is insufficient or poorly tolerated, administration of parenteral 
nutrition (PN) has been recommended, commencing as early as the first week of critical illness. PN is 
claimed to play a role in the development of cholestatic liver dysfunction [8] and the mechanisms 
behind PN-induced cholestasis may include alterations in bile composition and transport as well as 
direct toxicity by bile acids to the hepatocytes. 
 
In this study we aimed to investigate whether fasting, by withholding PN, limits cholestatic liver 
dysfunction in a rabbit model of prolonged critical illness. We compared the impact of fasting with 
PN-feeding during the first week of critical illness on serum levels of ALT, AST and bile acids and 
correlated these findings with the expression profiles of hepatobiliary transporters and nuclear 
receptors involved in the regulation of transport and metabolism of bile acids and bilirubin. 
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4.3. Materials and methods 
 
Experimental study design 
 
The study was performed in a validated rabbit model of prolonged critical illness that comprised the 
combination of a reproducible third degree burn injury and central vascular access. This model 
closely mimics the clinical, metabolic and endocrine abnormalities of critically ill patients [9-11]. The 
model has been described in detail previously [9-11]. In brief, 3-month-old male New Zealand White 
rabbits were anesthetized and catheters (for blood sampling, intravenous nutrition and insulin 
administration) were placed under general anesthesia and a full thickness burn injury equaling 15–
20% of the total body surface area was inflicted on the flanks after performing a paravertebral block. 
Next, animals were transferred to individual cages and fluid resuscitation was started with Hartmann 
solution (Baxter, Lessiness, Belgium) supplemented with 5% glucose (16 mL/h). Blood glucose levels 
were kept normoglycemic (targeted below 110 mg/dL) with insulin infusion. The animals were 
deprived from oral feeding but had free access to water and a small amount of hay. On day 1, rabbits 
were allocated to a fed group receiving a balanced mixed-component parenteral nutrition (84% 
glucose, 11% protein and 5% lipids) for 6 days (280 kCal/day) or a fasted group that only received 
dextrose 1.4% with 0.03% NaCl (14 kCal/day). On day 7, animals were sacrificed and samples were 
taken from liver and snap-frozen in liquid nitrogen. The energy content and composition of the 
parenteral nutrition is well within the physiological requirement for healthy rabbits. Thereafter, 
samples were stored at -80°C until further analysis (Figure 4.1). The study was approved by the KU 
Leuven Ethical Review Board for Animal Research and all animals were treated according to the 
Principles of Laboratory Animal Care (US National Society for Medical Research) and the Guide for 
the Care and Use of Laboratory Animals (National Institutes of Health). 
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Figure 4.1 Schematic overview of the study protocol 
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Quantification of serum and liver bile acids levels 
 
Individual serum bile acids were quantified by high performance liquid chromatography-mass 
spectrometry using authentic bile acid standards and deuterated internal standards. Serum samples 
(50 μL) were diluted with 50 μL of methanol containing 20.5 ng of deuterated internal standard 
(cholic acid). The samples were vortexed for 30 seconds, followed by centrifugation at 10,000 rpm 
for 10 minutes. 150 µL of the supernatant was transferred to a clean Eppendorf tube and dried under 
nitrogen gas. Samples were reconstituted in 100 µL of the assay mobile phase. Typical recoveries of 
extracted bile acids exceeded 85%. Chromatographic separations were carried out with a Waters 
2695 pump equipped with an autoinjector. The analytes were separated on a Phenomenex Synergi 
4μ Hydro-RP 80Å. The mobile phase consisted of solvent A (water), solvent B (methanol), and solvent 
C (100 mm ammonium acetate, pH 4.5) delivered as a gradient: 0–5 min for solvent B, 55%; 5-15 min 
for solvent B, 55-75%; 15-23 min for solvent B, 75-80% and 35-40 min for solvent B, 55% with 10% 
solvent C at a constant flow rate of 0.2 mL/min. The high performance liquid chromatography was 
coupled with a Waters ZQ quadruple mass detector via an electrospray ionization interface operating 
in the negative ion mode. Quantitative determination of bile acids was performed by time scheduled 
single ion recordings using (M – H)- ions. We determined the optimal parameters for the mass 
spectrometer for bile acid detection as follows; capillary voltage 3 kV, cone voltage 40 V, extractor 
voltage 5 V, and RF lens 0.3 V. Source temperature was 100°C and desolvation temperature 300°C. 
Desolvation gas flow was set at 350 L/h and cone gas flow rate was 60 L/h. The detection limit for 
individual bile acids was 10 to 50 nmol/L. Total serum and liver bile acid levels were measured 
enzymatically using a bile acid assay kit in accordance with manufacturer’s protocol (Diazyme, 
Germany). Liver tissue was weighed and homogenized in 75% ethanol and incubated at 50°C for 2h 
to extract bile acids and centrifuged at 6000g for 10min at 4°C. The bile acid content of the 
supernatant was determined and normalized with tissue weight used. Alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) were measured by an automated assay using Modular 
Roche and specific reagents (Roche/Hitachi, Bern, Switzerland). 
 
Cloning of rabbit genes of bile salt transporters and nuclear receptors 
 
For OATP1, OATP8, MRP4, MDR3, CAR (NR1I3), and RXRA (NR2B1) mRNA sequences were not 
available. Therefore, total RNA was isolated from rabbit liver tissue using Qiazol lysis reagent 
(Qiagen, Maryland, USA) and subsequently purified using the RNeasy mini RNA isolation kit (Qiagen). 
cDNA was obtained by reverse transcription of 1 µg total RNA with Super Script III Reverse 
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Transcriptase (Invitrogen) using random hexamer primers (Invitrogen).Partial coding sequences were 
synthesized by a PCR procedure using oligonucleotides designed by comparing homology of 
published sequences from other species. When possible, oligonucleotides surrounded the start and 
stop codon. Missing 3’ ends were cloned by RACE procedure. The amplified fragments were cloned 
into the pGEM-T vector (Promega) followed by sequence analysis (LGC, Germany). These sequences 
showed high amino acid identity with the corresponding genes from other mammalian species and 
data have been submitted to the GenBank database (listed in Supplemental table 4.1). Based upon 
these sequences, specific primers and probes for real-time PCR analysis were designed using Primer 
Express software 3.0 (Applied Biosystems, Foster City, CA) and subsequently customized (Eurogentec, 
Seraing, Belgium). 
 
RNA isolation and real-time PCR 
 
Total RNA was isolated as described above. All liver samples were reverse transcribed 
simultaneously. Reactions lacking reverse transcriptase were also run as a control for genomic DNA 
contamination. mRNA levels were quantified in fast real-time PCR with the StepOnePlus platform 
(Applied Biosystems, Lennik, Belgium) using TaqMan chemistry for accurate quantification of mRNA 
levels. Sequences of the primers and probes are listed in Supplemental table 4.1. The10 µL real time 
reaction mixture contained 5 µL TaqMan Fast Universal PCR Master Mix (Applied Biosystems, Foster 
City, CA), 0.5 µL forward primer, 0.5 µL reverse primer, 0.5 µL TaqMan probe (*5’+6-FAM*3’+BHQ-1 
labeled), 0.5 µL water, and 3µL cDNA (7.5 ng). Final concentrations were 900 nM for the primers and 
300 nM for the probes. Unknown samples were run in duplicate and individual samples with a CT 
value standard deviation greater than 0.3 were reanalyzed. Gene expression of ribosomal protein 
S18 (RPS18) remained stable in all study groups and was therefore used as an internal control. Data 
are expressed as a fold increase of the mean of the fed group. 
 
Immunoblot analysis 
 
Fifty mg of frozen liver tissue was homogenized with a Precellys 24 machine using ceramic beads 
(Bertin technologies, Montigny-le-Bretonneux, France) in lysis buffer containing phosphatase 
inhibitors (Halt Phosphatase Inhibitors Cocktail, Thermo Scientific, Aalst, Belgium). The protein 
content in the homogenate was determined by the Coomassie Protein Assay Reagent (Thermo Fisher 
Scientific, Aalst, Belgium). Equal amounts of homogenate proteins (20 µg) were separated by 
 54  
denaturing SDS gel electrophoresis in 10% Bis-Tris or 3-8% tris-acetate polyacrylamide gels (Bio-Rad 
Laboratories, Nazareth, Belgium) and separated proteins transferred to nitrocellulose membranes 
(Hybond, Ammersham Biosciences). Membranes were incubated overnight at 4°C with primary 
antibody and HRP-linked secondary antibody for 1 hour at room temperature. Further information 
on the source and dilutions of the primary antibodies for MRP3, MRP4, CYP7A1, CK18 (Abcam, 
Cambridge, UK), BSEP (Santa Cruz Biotechnology, Santa Cruz, USA), MRP2, and secondary antibodies 
(DAKO, Denmark) are listed in Supplemental table 4.2. For NTCP, OATP1, OATP8, OSTα, MDR1, and 
MDR3 no commercially available anti-rabbit antibodies were found. Immunoblots were developed 
using enhanced chemiluminescence technology (PerkinElmer, Vilvoorde, Belgium) and analyzed using 
ImageMaster Software 1D Elite (GE Healthcare Europe GmbH, Diegem, Belgium). Data were 
normalized for cytokeratin 18 (CK18) as a loading control. 
 
Statistical analysis 
 
Statistical analysis was performed using Statview 5.0.1 (SAS Institute, Cary, NC). All quantitative 
values were assessed for normality. Data were presented as mean  SEM or medians with IQR (1st-
3rd) when appropriate. Paired measurements of the circulating bile acids were analyzed with 
Wilcoxon Signed Rank tests. Differences among study groups were analyzed by unpaired t-tests for 
normally distributed data and by Mann-Whitney U tests for non-normally distributed data. 
Correlations were calculated using Pearson tests. For all tests a p-value less than 0.05 was deemed 
significant. 
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4.4. Results 
 
Circulating levels of ALT, AST and bile acids 
 
After 7 days of critical illness, serum levels of the AST and ALT were lower in fasted compared to PN-
fed critically ill rabbits (Figure 4.2). In contrast, the levels of total bile acids in the serum were not 
different between PN-fed and fasted critically ill rabbits (Figure 4.2). However, critical illness induced 
a shift in the composition of the circulating bile acid pool (Figure 4.3). In rabbits, unconjugated cholic 
acid (CA), deoxycholic acid (DCA), lithocholic acid (LCA) and hyodeoxycholic acid (HDCA) are the main 
circulating bile acids. If conjugated, they are predominantly glycine-bound. Median healthy baseline 
levels of CA were 0.14 µM (IQR 0.07 – 0.36), of DCA were 7.59 µM (IQR 3.62 – 18.52), of LCA were 
0.38 µM (IQR 0.18 - 0.78), of HDCA were 2.76 µM (IQR 1.63 – 4.48), of G-CA were 0.16 (IQR 0.05 – 
0.21) and of G-DCA were 0.34 (IQR 0.12 – 0.86). Compared to baseline values, PN-fed rabbits 
displayed lower unconjugated CA and DCA levels, whereas in fasted rabbits only unconjugated DCA 
levels were not altered. Unconjugated LCA was increased comparably in both PN-fed and fasted 
critically ill rabbits, whereas HDCA was unaffected by critical illness. In contrast, conjugated glyco-
deoxycholic acid (G-DCA) was increased in fasted critically ill rabbits, but not in PN-fed rabbits. This 
shift from unconjugated to conjugated bile acids in fasted animals was reflected in a 10- to 15-fold 
increase of the G-CA/CA ratio and G-DCA/DCA ratio in fasted rabbits. PN-fed rabbits displayed a 3-
fold increase in the G-CA/CA ratio (Figure 4.3). 
 
 56  
 
 
Figure 4.2 Serum TBA, ALT and AST and liver TBA and CYP7A1 in PN-fed and fasted prolonged 
critically ill rabbits 
 
TBA serum shows day 7 circulating total bile acid concentration, ALT and AST AUC is the area under the curve 
using daily measurements, TBA liver and CYP7A1 shows the day 7 values quantified in liver homogenates. 
Median healthy baseline levels were 13.0 µM (IQR 7.5-18.9) for TBA, 41 U/L (IQR 31-61) for AST, and 30 U/L 
(IQR 18-61) for ALT. Levels are expressed as median with IQR (25th-75th percentiles). Abbreviations: TBA, total 
bile acids; AUC, area under the curve; OD, optical density. 
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Figure 4.3 Circulating bile acid concentrations in TPN-fed and fasted critically ill rabbits 
 
Bile acids were determined by mass spectrometry at baseline (BL) and day 7 (d7) after onset of the illness and 
are expressed as the delta change from baseline. Levels are expressed in µM and are represented as median 
with IQR. * represents p≤0.05 for comparison of changes over time (baseline levels versus day 7 levels) using 
the Wilcoxon Signed Rank test. The p-values depicted on each panel were calculated using the nonparametric 
Mann-Whitney U test for comparison of the differences over time between the fed and the fasted animals. 
Abbreviations: CA, cholic acid; DCA, deoxycholic acid; LCA, lithocholic acid; HDCA, hyodeoxycholic acid; G-CA, 
glycocholic acid; G-DCA, glycodeoxycholic acid. 
 
 
 
Bile acid synthesis enzymes and hepatobiliary transporters  
 
Hepatic protein levels of CYP7A1, the rate limiting enzyme in the bile acid synthesis, were not 
different between TPN-fed and fasted critically ill rabbits (Figure 4.2). Protein levels correlated well 
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with mRNA levels of CYP7A1 (r=0.515; p=0.02). No correlation between the serum levels of total bile 
acids and hepatic mRNA or protein CYP7A1 levels was observed. 
Hepatic protein levels of the basolateral bile acid efflux transporters MRP3 and MRP4 were 
significantly higher in fasted compared with PN-fed critically ill rabbits (Figure 4.4). MRP3 and protein 
levels correlated inversely with mRNA levels (r=-0.553, p=0.009) and MRP4 protein levels did not 
correlate with mRNA levels. Gene expression of OSTα was not altered (Supplemental figure 4.1). 
 
We could not quantify protein levels of the basolateral uptake transporters NTCP, OATP1 and OATP8, 
but mRNA levels of NTCP (p=0.0003) and OATP8 (p=0.002) were lower in fasted compared with PN-
fed critically ill rabbits (Supplemental figure 4.1). 
 
Hepatic protein levels of the canalicular efflux pump MRP2 were lower in fasted compared with PN-
fed critically ill rabbits (Figure 4.4). MRP2 protein levels correlated positively with MRP2 mRNA levels 
(r=0.871, p<0.0001). In contrast, the canalicular efflux pump BSEP protein levels were higher in fasted 
compared with PN-fed critically ill rabbits. However, BSEP protein levels did not correlate with BSEP 
mRNA levels. We could not quantify protein levels of the canalicular efflux pumps MDR1 and MDR3, 
but gene expression levels were lower in fasted compared with TPN-fed critically ill rabbits (p=0.0007 
for MDR1, p=0.0004 for MDR3, Supplemental figure 4.1). 
 
 
 
Figure 4.4 Protein levels of hepatobiliary transporters in PN-fed and fasted prolonged critically ill 
rabbits 
 
Hepatic basolateral efflux transporters (MRP3, MRP4), and canalicular efflux pumps (BSEP, MRP2) were 
quantified by Western blot using liver homogenates. Data are represented as median with IQR (25th-75th 
percentiles). Abbreviations: MRP, multidrug resistance-associated protein; BSEP, bile salt export pump, OD 
optical density. 
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Nuclear receptors 
 
To identify the upstream regulators of the transporter expression levels, we quantified gene 
expression of the key regulating nuclear receptors. In normal physiological conditions farnesoid X 
receptor (FXR) is the predominant bile acid sensor, but also retinoid X receptor alpha (RXRA), the 
vitamin D receptor (VDR), pregnane X receptor and constitutive androstane receptor (CAR) are 
involved in the regulation of BA metabolism and/or transport [12].  
 
Gene expression levels of the nuclear receptors FXR and CAR were significantly lower in fasted 
compared with PN-fed critically ill rabbits (Figure 4.5). mRNA levels of FXR correlated inversely with 
the protein levels of the basolateral efflux pumps MRP3 and MRP4 and positively with the protein 
levels of the canalicular efflux pump MRP2 (Figure 4.5). Gene expression of the nuclear receptor 
RXRA was higher in fasted compared with PN-fed critically ill rabbits and correlated positively with 
MRP3 protein levels (Figure 4.5). Gene expression of the nuclear receptors PXR and VDR did not 
differ between the 2 study groups. 
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Figure 4.5 (A) Gene expression levels of nuclear receptors in PN-fed and fasted prolonged critically 
ill rabbits. (B) Correlations between nuclear receptors and hepatobiliary transporters 
 
Data in (A) are represented as median with IQR (25th-75th percentiles). Abbreviations: FXR, farnesoid X 
receptor; VDR, vitamin D receptor; CAR, constitutive androstane receptor; PXR, pregnane X receptor; RXRA, 
retinoid X receptor alpha. AU, arbitrary units, MRP multidrug resistance-related protein. 
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4.5. Discussion 
 
This study in a rabbit model of prolonged critical illness found that fasting by withholding PN reduced 
markers of hepatocellular injury and induced a shift towards more conjugated and less toxic bile 
acids. Fasting during critical illness was also associated with an increased protein expression of the 
bile acid efflux transporters at the basolateral (MRP3) and apical (BSEP) membranes. The increased 
expression of MRP3 was strongly associated with suppression of FXR.  
 
Fasting during prolonged critical illness in rabbits resulted in decreased levels of AST and ALT, 
indicating suppressed parenchymal damage. Parenchymal liver damage during critical illness, also 
called hypoxic liver injury [13], is associated with poor outcome in the ICU [14]. This is in contrast 
with the findings from a randomized controlled trial in adult critically ill patients [15]. Here, 
withholding PN during the first week of critical illness did not affect the number of patients with a 
clinically important increase in levels of AST and ALT. Surprisingly, fasting by withholding PN resulted 
in a higher proportion of patients with hyperbilirubinemia during the first week of critical illness. In 
the critically ill rabbits we could not detect bilirubin in the serum, neither by the conventional 
enzymatic essays nor by High Performance Liquid Chromatography. For this reason we focused on 
the bile acids as markers of cholestasis. Withholding PN did not affect the concentration of total bile 
acids in the serum or in the liver. Nevertheless, fasting induced a shift towards more conjugated bile 
acids. This indicates a protective response as conjugated bile acids are less toxic than their 
unconjugated counterparts. In critically patients the unconjugated bile acids, cholic acid and 
chenodeoxycholic acid, did not differ from controls, but went together with a large increase in the 
concentration of conjugated bile acids [6]. Similarly, the change in bile acid concentration could not 
be explained by increased de novo bile acid synthesis as the protein expression level of CYP7A1 was 
unaltered [6].  
 
Hence, changes in the transport of the bile acids between the hepatocyte, the sinusoidal blood 
compartment and the canalicular bile compartment are most likely controlling the altered bile acid 
composition during critical illness. The strong upregulation of the basolateral efflux transporters 
MRP3 and MRP4 by fasting is striking. Under normal conditions these transporters exhibit only low 
expression levels in hepatocytes. Prolonged critical illness [6], inflammation [16] and longstanding 
cholestasis [17] have been associated with increased MRP3 and MRP4 expression. It is presumed that 
that the basolateral efflux transporters reverse the transport of primarily conjugated bile acids from 
the canalicular bile compartment to the blood for subsequent renal elimination. The observations 
that withholding PN reduced markers of hepatocellular injury in combination with increased MRP3 
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and MRP4 expression suggests that MRP3/4 upregulation is a protective response, at least from the 
standpoint of the liver. Whether the increased levels of bile acids and bilirubin, and the shift towards 
more conjugated bile acids in critically ill patients [6] and animals [18] holds a survival benefit is not 
clear. It suggests that the association between the increase of bilirubin levels during the first 48 
hours after ICU admission and the risk of mortality described in an observational study [1] may not 
be causal. However, in other studies serum bilirubin levels were found to be a poor discriminator of 
increased mortality risk during critical illness [19;20].  
 
In observational studies during critical illness, artificial nutrition has been associated with the 
development of liver dysfunction [21;22]. The EPaNIC randomized controlled trial demonstrated that 
withholding PN lead to fewer patients with a clinically important increase in levels of GGT and ALP 
during the entire ICU stay, suggesting less cholestatic liver dysfunction [15]. Nevertheless, the 
proportion of patients with hyperbilirubinemia was higher in the late PN group. As this patients 
group had a shortened ICU stay, less new infections in the ICU and a faster recovery from organ 
failure, one can question whether hyperbilirubinemia alone is an appropriate marker of poor ICU 
outcome.  
 
The metabolism and transport of the bile acids is tightly regulated by a complex network of nuclear 
receptors, of which FXR is the most important. Critical illness leads to decreased levels of FXR and its 
heterodimeric partner RXRA in the nucleus of the hepatocytes [6]. Fasting during critical may lead to 
a further decrease in the levels FXR. However, the gene expression levels of RXRA were increased by 
withholding PN in this rabbit study of critical illness. As we previously described discrepant responses 
between the gene and protein expression level, interpretation of the data should be done with 
caution [6]. However, taken that withholding PN during critical illness holds a beneficial response, 
reduced expression of the bile acid sensor FXR, maintenance of bile acid synthesis (CYP7A1) and 
reversal of bile acid transport (MRP3) may constitute a protective response. Indeed, previous studies 
in bile duct ligated mice have demonstrated that genetic abrogation of Fxr reduces liver injury and 
improves survival, accompanied by strong upregulation of the basolateral BA efflux transporter Mrp4 
[23;24], a direct parallel of what was observed in the present study. This suggests that FXR 
antagonists may be therapeutically useful across a ranges of conditions where bile acids contribute 
to liver injury. 
 
Alternatively, the changes in bile acid metabolism and transport may reflect a dysfunctional feedback 
system and may herald poor outcome [20]. Starvation in non-critical care conditions gives rise to 
exacerbated liver apoptosis in FXR knock-out mice [25]. 
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This study has some limitations. First, extrapolation from an animal model of critical illness to the 
human context is difficult. This was further complicated by the difficulty encountered in measuring 
bilirubin levels and protein levels of the basolateral bile acid transporters OATP and NTCP. Secondly, 
although animals were randomized into two groups, the association between the bile acids, their 
transporters and the regulating nuclear receptors cannot delineate causality. Future studies in which 
those components of bile acid regulation are manipulated by overexpression and knock-out models 
could provide additional mechanistic insight. Thirdly, sham-operated, pair-fed animals were not 
added to the study. This was done as the key question was the impact of parenteral nutrition versus 
nutrient restriction during critical illness. 
 
In conclusion, during prolonged critical illness, withholding PN improved markers for hepatocellular 
injury in association with the reversal of normal bile acid trafficking and increased bile acid 
detoxification though conjugation. This suggests that fasting in critical illness induces adaptive 
changes in bile acid homeostasis, changes that could possibly be emulated by therapeutic 
interventions targeting FXR [12;26]. 
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Supplemental data 
 
 
Supplemental figure 4.1 Gene expression of hepatobiliary transporters in PN-fed and fasted 
critically ill rabbits. 
 
 
 
Hepatic basolateral influx pumps (NTCP, OATP1, OATP8), basolateral efflux transporters (MRP3, MRP4, OSTα), 
and canalicular efflux pumps (BSEP, MRP2, MDR1, MDR3). mRNA levels are expressed in arbitrary units relative 
to the mRNA expression of the housekeeping gene RPS18 and relative to 10 fed critically ill rabbits. Data are 
represented as median with IQR (25
th
-75
th
 percentiles). Abbreviations: NTCP, Na
+
/taurocholate cotransporting 
polypeptide; OATP, organic anion transporting polypeptide; MRP, multidrug resistance-associated protein; OST, 
organic solute transporter; BSEP, bile salt export pump; MDR, multidrug resistance protein. 
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Supplemental table 4.1 Primers and probes for real-time PCR gene expression analyses 
 
Name  NCBI Accession number  Sequence  
5’-Fw primer-3’ 
5’-Rv primer-3’ 
5’-Probe-3’ 
NTCP  NM_001082768.1 5’-TCTCTGCCCTGATGCCTTTT-3’ 
5’-CGTGCACTAAGGCGGAAGA-3’ 
5’-TGGCTTCCTGCTGGGCTTCATTCTCT-3’ 
OATP1  KC708581 5’-CTTTTTGATTTGTGCAGGAGTGA-3’ 
5’-GATTATCCTCTAGTCCTTCCTTTGGA-3’ 
5’-TGTGCTCACTGCCATCCCTTTTTTCTTT-3’ 
OATP8  KC708580 5’-GAATGGTATGGAAGCAATAATGGAT-3’ 
5’-GGATGCTCGATGGGTTGGT-3’ 
5’-ATTCCAGCCATAAGGAAACCAAGCCACC-3’ 
MRP3  AY289920.1  5’-GCAATTACTCAGAGGAGGACATCTG-3’ 
5’-GCTGCGCCCTCACGAA-3’ 
5’-CAAGCCCTGGAGCTGGCCCAC-3’ 
MRP4  KC708579 5’-TTGCAAGCAAAATCATCGTGTT-3’ 
5’-CACGGCTGGCTGTGATGAC-3’ 
5’-ACCTTCACAGTCTATGTGCTCCTGGGCAA-3’ 
OSTα  DQ122755.1  5’-GTGCTCACCAGGAAGAAGCTTAA-3’ 
5’-GCGAGATCTTGAAGAACGCATA-3’ 
5’-CTGCTGATGTTGGGCCCATTCCA-3’ 
MDR1  NM_001082159.1  5’-AACTGGAAGGTTCCGGAAAGA-3’ 
5’-CTTCTGCTCACGAGTCAGAGACA-3’ 
5’-TGCCACAGAAGCAATAGAGAACTTCCGAA-3’  
MDR3  KC708578 5’-TTCTGGTGTTCTCAGCAATCGT-3’ 
5’-GCGTAGTCCGGAGCAAAGG-3’ 
5’-CGGTGGCTCTCGGACACGCC-3’ 
BSEP  NM_001082083.1  5’-GAGGGAACTACCAGGACAGTTTAAGA-3’ 
5’-TGCCAGGTAAGAAAGCTGAGACT-3’ 
5’-CGTCTCTCCGGCAGCGCTCC-3’ 
MRP2  Z49144.1 5’-GCTTTCCCATGAGCATGCTT-3’ 
5’-GCCGATCCACGGAAACACT-3’ 
5’-CCAATGTGATCTCCGCCATGCTCC-3’ 
FXR 
NR1H4 
NM_001082726.1 5’-CAAGATTCATCAGCCCGAGAA-3’ 
5’-AACGTCCGCAGCTCTGTCA-3’ 
5’-CCTCAACACTTCGCCTGCCTCCTG-3’ 
CAR 
NR1I3 
KC708577 5'-TCAGACGAACGGTCAATAAATACC-3' 
5'-GGCCCTGCTGACCTCACA-3' 
5'-TCTCACCTGCCCCTTTGCTGG-3' 
PXR 
NR1I2 
NM_001082067.1 5'-GCTGACAGAAGTGGGAAAAAGC-3' 
5'-ATGCCTTTGAACATGTAGGTTGAC-3' 
5'-TTTTCTCTGCTGCCCCACTTGGCTG-3' 
VDR 
NR1I1 
AY262279.1 5’-AGCAGCAGCGCATCATTG-3’ 
5’-GGCATAGGTAGGGTCGTAGGTCTT-3’ 
5’-CATCCTGCTGGACGCCCACCA-3’ 
RXRA 
NR2B1 
KC708576 5’-ATGGCCAGGCACTTCTGGTA-3’ 
5’-AAGGACTGCCTGATCGACAAG-3’ 
5’-CGGCAGTACTGGCACCGGTTCC-3’ 
CYP7A1 NM_001170929.1 5’-CAGGGACCACATCTCAGAACTG-3’ 
5’-CGTCGAAGGTGGAGAGTGTGT-3’ 
5’-TCCGCCTGCGCATGTTTCTGAA-3’ 
RPS18 KC708528 5’-TTCCGCATGATGGTGATCAC-3’ 
5’-GCAGACATTGACCTGACCAAGA-3’ 
5’-CGTTCCACCTCGTCCTCAGTGAGCTCT-3’ 
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Supplemental table 4.2  Primary and Secondary Antibodies for immunoblotting 
 
Antibody Species Clone Dilution Company 
MRP3 Mouse M2II-21 (Ab3376) 1:50 Abcam 
MRP4 Mouse M4I-10 (Ab15602) 1:50 Abcam 
BSEP Mouse F-6 (Sc-74500) 1:100 Santa Cruz 
MRP2 Guinea Pig C-terminal 1:1000 Gift* 
CYP7A1 Rabbit C-terminal (Ab79847) 1:200 Abcam 
CK18 Mouse C-04 (ab668) 1:10000 Abcam 
Anti-mouse IgG/HRP Goat P0447 1:1000 Dako 
Anti-rat IgG/HRP Rabbit P0450 1:1000 Dako 
Anti-rabbit IgG/HRP Goat P0448 1:1000 Dako 
Anti-guinea pig IgG/HRP Rabbit P0141 1:1000 Dako 
 
Abbreviations: MRP, multidrug resistance-associated protein; BSEP, bile salt export pump; CK, cytokeratin; Ig 
immunoglobulin; HRP horse radish peroxidase. * MRP2 antibody was a kind gift from Prof. F.G.M. Russel, 
University of Nijmegen, The Netherlands [1]. 
 
Reference List 
 1.  van Aubel RA, Hartog A, Bindels RJ, van Os CH, Russel FG: Expression and immunolocalization 
of multidrug resistance protein 2 in rabbit small intestine. Eur J Pharmacol 2000;400:195-198. 
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Chapter 5: 
Withholding parenteral nutrition during critical illness increases plasma 
bilirubin but lowers the incidence of biliary sludge 
 
 
This chapter is in press: 
Vanwijngaerden Y-M, Langouche L, Brunner R, Debaveye Y, Gielen M, Casaer M, Liddle Ch, Coulter S, 
Wouters PJ, Wilmer A, Van den Berghe G, Mesotten D. Withholding parenteral nutrition during 
critical illness increases plasma bilirubin but lowers the incidence of biliary sludge. Hepatology. 2013 
Nov 9. [Epub ahead of print] 
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5.1. Abstract  
 
Cholestatic liver dysfunction (CLD) and biliary sludge often occur during critical illness and are 
allegedly aggravated by parenteral nutrition (PN). Delaying initiation of PN beyond day 7 in ICU (late 
PN) accelerated recovery as compared with early initiation of PN (early PN). However, the impact of 
nutritional strategy on biliary sludge and CLD has not been fully characterized. 
 
This was a preplanned subanalysis of a large RCT of early PN versus late PN (n=4640). In all patients 
plasma bilirubin (daily) and liver enzymes (ALT/AST/GGT/ALP; twice weekly; n=3216) were 
quantified. In a random predefined subset of patients also plasma bile acids (BAs) were quantified at 
baseline and on days 3, 5 and last ICU day (n=280). Biliary sludge was ultrasonographically evaluated 
on ICU day 5 (n=776). 
 
From day 1 after randomization until the end of the 7-day intervention window, bilirubin was higher 
in the late PN than in the early PN group (p<0.001). In the late PN group, as soon as PN was started 
on day 8, bilirubin fell and the two groups became comparable. Maximum levels of GGT, ALP and ALT 
were lower in the late PN group (p<0.01). Glycine/taurine-conjugated primary BAs increased over 
time in ICU (p<0.01), similarly for the two groups. Fewer patients in the late PN than in the early PN 
group developed biliary sludge on day 5 (37% vs 45%; p=0.04). 
 
In conclusion, tolerating substantial caloric deficit by withholding PN until day 8 of critical illness 
increased plasma bilirubin but reduced the occurrence of biliary sludge and lowered GGT, ALP and 
ALT. These results suggest that hyperbilirubinemia during critical illness does not necessarily reflect 
cholestasis and instead may be an adaptive response that is suppressed by early PN. 
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5.2. Introduction 
 
Cholestatic liver dysfunction (CLD) – most typically defined as hyperbilirubinemia above 3 mg/dL - 
occurs in almost 20% of critically ill patients and is an independent risk factor for unfavorable 
outcome [1-3]. Hyperbilirubinemia is a common phenotype of numerous diseases and syndromes in 
critically ill patients. Mechanical obstruction of the extrahepatic bile duct is easily and robustly 
diagnosed by ultrasonography, but is only a rare cause of CLD in the intensive care unit (ICU). CLD is 
predominantly due to intrahepatic non-obstructive cholestasis, which is essentially the inability of 
the hepatocyte to secrete bile into the bile duct, leading to an intracellular accumulation of bilirubin 
and bile acids (BAs). Although increased concentrations of BAs inside the hepatocytes are the likely 
cause of cholestatic liver damage, plasma concentrations of bilirubin, and/or alkaline phosphatase 
(ALP) and gamma-glutamyl transferase (GGT) are mostly used in clinical practice for CLD diagnosis 
[4]. 
 
Biliary sludge may also be part of the spectrum of CLD during critical illness due to a lack of bile flow. 
Notably, critically ill patients with absent oral intake and on total parenteral nutrition are susceptible 
to the development of biliary sludge. This also applies to patients after gastric surgery or 
transplantation and patients in whom antibiotics such as ceftriaxone are used [5]. The clinical 
relevance of gallbladder sludge is however unclear and therapeutic interventions are reserved for 
patients who develop acalculous cholecystitis. 
 
Parenteral nutrition (PN) is assumed to aggravate both CLD and biliary sludge formation [6]. In a large 
randomized controlled multicenter trial we have recently assessed the outcome effect of tolerating a 
nutritional deficit during the first week in ICU (Late PN), compared with early initiation of PN to 
supplement insufficient enteral feeding (early PN) [7, 8]. Late PN enhanced organ function recovery, 
reduced the incidence of new infections and shortened duration of ICU stay. Strikingly, more patients 
in the late PN group had hyperbilirubinemia above 3 mg/dL, whereas fewer late PN patients had a 
clinically relevant increase in levels of GGT or ALP [8]. We therefore hypothesized that increased 
bilirubin levels during critical illness do not necessarily reflect onset of clinically significant CLD. In 
contrast, hyperbilirubinemia may represent an adaptive response, as bilirubin can act as an 
endogenous anti-oxidant and may counteract the pro-oxidative effects of BA [9-11]. 
 
Therefore, the aim of the present study was to compare the effect of late versus early PN on 
circulating bilirubin, BAs and the liver enzymes GGT, ALP, alanine aminotransferase (ALT), aspartate 
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aminotransferase (AST) over time. In addition, we evaluated the impact of late PN versus early PN on 
biliary sludge by ultrasonography on ICU day 5. 
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5.3. Material and methods 
 
Study design and patient characteristics 
 
This study was a preplanned prospective subanalysis of a large randomized controlled trial on the 
effect of early versus late initiation of PN on the outcome of critical illness (EPaNIC trial) [12]. The 
study protocol was previously described in detail [8]. Patients were allocated either to the early PN 
group, where PN was initiated within 48 hours after ICU admission to supplement insufficient enteral 
nutrition (early PN n=2312) or to the late PN group, where PN was not initiated before day 8 (late PN 
n=2328) (Figure 5.1). Baseline characteristics for both allocation groups were comparable in the total 
study population (Supplemental table 5.1). 
 
 
 
Figure 5.1 Total energy intake levels during the EPaNIC study 
 
Boxes represent daily total caloric intake (glucose, lipids and proteins) expressed as medians with IQR (25
th
-75
th
 
percentiles). The grey boxes represent daily caloric intake of patients randomized to receiving early parenteral 
nutrition (early PN), whereas open boxes are presenting values from patients randomized to nutrient 
restriction (late PN). The number of patients still in ICU is plotted for each day. Abbreviations: IQR interquartile 
range, PN parenteral nutrition, ICU intensive care unit. 
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Time course of bilirubin was assessed in all patients while in ICU (early PN n=2312; late PN n=2328). 
Liver enzymes ALT, AST, GGT and ALP were quantified twice weekly in all patients. Additionally, in 
3216 EPaNIC patients (early PN n=1760; late PN n=1794) also plasma conjugated bilirubin was 
quantified during ICU stay as part of the daily routine clinical practice. 
 
For determination of the plasma levels of conjugated and unconjugated bile acids and conjugated 
bilirubin, a subgroup of patients, identifiable upon ICU admission, was chosen. Only patients for 
whom early enteral nutrition was surgically contra-indicated were selected [8]. This selection was 
chosen to prevent possible bias by enterohepatic recycling of BA and bilirubin by enteral feeding. Of 
the 517 patients in this subgroup (256 patients in the early PN group and 261 patients in the late PN 
group) a random selection of 280 patients (140 out of each allocation group) was made to reduce the 
number of samples for analysis, while testing the hypothesis with enough statistical power. Random 
selection was performed by a computer algorithm (StatView software, SAS Institute Inc., Cary, North 
Carolina). Patients in the early and late PN group were comparable for baseline characteristics 
(Supplemental table 5.1). In this subgroup, nutritional intake was according to the study protocol 
(Supplemental figure 5.1). 
 
For analysis of the impact of early versus late PN on gallbladder sludge, all patients who were still in 
ICU on the morning of day 5 (early PN n=975, late PN n=913) were eligible for ultrasonography of the 
gallbladder (Figure 5.2). Patients with a history of cholecystectomy (n=90), patients who were 
moribund (n=2), or patients who were discharged from ICU on day 5 before 12 am (n=147) were 
excluded from the ultrasonography study. Additionally, 783 patients were excluded due to logistical 
reasons (such as unavailability of ultrasonography device or ultrasound assessor). In total 776 
patients (early PN n=420; late PN n=356) underwent ultrasonographical investigation of the 
gallbladder on day 5 of their ICU stay. Baseline characteristics in both treatment groups were 
comparable (Supplemental table 5.1). 
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Figure 5.2 Consortdiagram of enrollment for the ultrasonography study  
 
Only patients with an ICU stay of at least 5 days were selected for evaluation. Abbreviations: PN parenteral 
nutrition, ICU intensive care unit, US ultrasonography. 
 
 
Plasma concentrations of bilirubin, liver enzymes and bile acids 
 
Plasma total and conjugated bilirubin were quantified by a standard routine automated laboratory 
assays (colorimetric DPD-method, HITACHI/Roche for Cobas c702). Liver enzymes ALT, AST, GGT and 
ALP were quantified by standard routine automated laboratory assays (ALT and AST with the UV 
kinetic method according to the International Federation of Clinical Chemistry (IFCC), GGT with the 
Szasz kinetic colorimetric assay and ALP with an AMP kinetic colorimetric assay according to the IFCC, 
all Hitachi/Roche for Cobas c702). 
 
Plasma concentrations of unconjugated and conjugated primary bile acids cholic acid and 
chenodeoxycholic acid were measured, as well as the conjugated and the unconjugated secondary 
bile acid deoxycholic acid by high performance liquid chromatography-mass spectrometry by using 
authentic bile acid standards and deuterated internal standards, as previously described [13]. 
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Ultrasonography of the gallbladder 
 
Gallbladder sludge, wall thickness and wall doubling were evaluated by blinded assessors (YV, YD, 
MG) using ultrasonography. The diagnosis of gallbladder sludge was based on the presence of a low-
amplitude echogenic collection layering in the most dependent portion of the gallbladder. A 
thickened gallbladder wall (> 5mm) and wall doubling (presence of pericholecystic fluid) were 
assessed at the anterior part of the gallbladder. 
 
Statistical analysis 
 
Statistical analysis was performed with Statview 5.0.1 (SAS Institute Inc., Cary, North Carolina SAS). 
All quantitative values were assessed for normality. Values with normal distribution, and those that 
were normalized after logarithmic transformation, were compared with the unpaired and paired 
Student’s t-test. The non-normally distributed data were compared by the non-parametric Mann-
Whitney U-test and Wilcoxon signed rank test. Nominal and ordinal variables (expressed as numbers 
and percentages) were compared with Fisher’s exact test. Correlations between variables were 
calculated using the Pearson’s rank correlation test. For all tests a p-value less than 0.05 was deemed 
significant. To assess the potential predictive power of circulating bilirubin and/or bile acids, area 
under the receiver operator characteristics curve (AROC) values were calculated with SPSS software 
(SPSS version 2.0, IBM Corp, New York, USA). Additionally, the relationship between categorized day 
1 bilirubin levels and mortality of all EPaNIC patients was plotted. 
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5.4. Results 
 
Effect of late initiation of parenteral nutrition on bilirubin and the other liver enzymes tests 
 
Peak plasma levels of total bilirubin determined during the whole ICU stay and determined during 
the study intervention window (first 7 days in ICU) were higher in late PN patients in comparison with 
early PN patients (Table 5.1). From day 1 after randomization until the end of the 7-days intervention 
window, also daily plasma total bilirubin was higher in the late PN than in the early PN group (all 
p<0.001) (Figure 5.3). From day 8 onwards, when PN was commenced in late PN patients and total 
caloric intake levels became comparable in both groups, plasma total bilirubin was no longer 
different between late and early PN patients. In the subgroup of patients admitted with sepsis (early 
PN n=510, late PN n=505) changes were comparable to those in the total population: bilirubin levels 
were higher in late PN patients from day 2 until day 8 (p<0.05) and became similar in the two groups 
from day 8 onwards. Conjugated bilirubin levels quantified during clinical routine in 3216 EPaNIC 
patients correlated with total bilirubin (r>0.900 and p<0.01 for all) and were higher in late PN 
compared to early PN patients (p<0.05 until day 7). Also, peak levels of conjugated bilirubin were 
higher in late versus early PN patients (Table 5.1). In the total patient population, conjugated levels 
represented 80% of total bilirubin. 
 
 
Table 5.1 Effect of early versus late parenteral nutrition on peak plasma concentrations of total 
bilirubin and liver enzymes 
 
 ICU D1-LD ICU D1-D8 
 Early PN Late PN p-value Early PN Late PN p-value 
T Bilirubin (mg/dL) 0.91 [0.60-1.64] 1.01 [0.67-1.78] < 0.0001 0.87 [0.59-1.48] 0.97 [0.65-1.66] < 0.0001 
C Bilirubin (mg/dL) 0.39 [0.21-1.01] 0.45 [0.24-1.16] 0.0003 0.37 [0.20-0.85] 0.43 [0.24-1.02] < 0.0001 
GGT (IU/L) 50 [19-140] 38 [18-115] 0.0007 40 [18-99] 35 [17-84] 0.002 
ALP (IU/L) 178 [102-373] 159 [99-332] 0.02 155 [100-275] 149 [97-257] 0.1 
ALT (IU/L) 28 [16-79] 24 [14-65] 0.0003 23 [14-51] 21 [14-45] 0.005 
AST (IU/L) 55 [34-106] 55 [33-104] 0.3 50 [32-87] 50 [32- 92] 0.9 
 
Peak plasma concentrations of total bilirubin and liver enzymes for the total EPaNIC study ICU stay and for the 
EPaNIC study intervention time window (first 8 days of ICU stay) are presented as median [IQR]. P-values are 
calculated with Mann-Whitney U test. Abbreviations: ICU intensive care unit, C conjugated, T total, GGT 
gamma-glutamyl transferase, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate 
aminotransferase 
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Figure 5.3 Daily plasma total bilirubin levels  
 
Daily plasma total bilirubin levels of all patients still in ICU are presented as mean ± standard error of the mean. 
The grey dots present values of early PN patients, whereas open dots are presenting values from late PN 
patients. * p≤0.05 with the unpaired Student’s t-test after logarithmic transformation. Abbreviations: PN 
parenteral nutrition, ADM admission. 
 
 
In contrast with bilirubin, peak levels of GGT were lower in the late PN group compared with the 
early PN group determined during the total ICU stay as well as during the study intervention window 
(Table 5.1). Peak levels of ALP were also lower in the late PN group in comparison with the early PN 
group, but only when determined over the total ICU stay. Peak levels of the hepatocyte lysis enzyme 
ALT were lower in the late PN group compared to the early PN group during the total ICU stay as well 
as during the study intervention window. Peak levels of AST did not differ between the 2 treatment 
groups (Table 5.1). 
 
Effect of late initiation of parenteral nutrition on bile acids and conjugated bilirubin 
 
In the subset of patients for whom early enteral nutrition was surgically contra-indicated, circulating 
BAs were determined by mass-spectrometry. In these patients, compared with the admission values, 
the circulating glycine- and taurine-conjugated primary BAs, cholic acid and chenodeoxycholic acid, 
were elevated on day 3 and day 5 of ICU stay (Figure 5.4). Also, the unconjugated primary BA cholic 
acid was mildly increased on day 3 and day 5. Remarkably, the concentration of conjugated cholic 
acid was 5- to 50-fold higher than the levels of unconjugated cholic acid (p<0.01 for all – Figure 5.4). 
The secondary BA, deoxycholic acid, either unconjugated or conjugated, did not change over time in 
these critically ill patients. The levels of circulating bile acids were comparable in early and late PN 
patients. In this subgroup of patients, conjugated bilirubin levels correlated well with the total 
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bilirubin levels on admission, on day 3 and day 5. They were higher in the late PN patients compared 
to the early PN patients (Figure 5.5). Of the total bilirubin levels, 35% was conjugated. 
 
 
 
Figure 5.4 Circulating plasma levels of bile acids 
 
Plasma levels of bile acids (expressed in µM) on admission, on day 3 and day 5 of ICU stay are represented as 
median with IQR (25
th
-75
th
 percentiles). The grey dots present values of early PN patients (n=140), whereas 
open dots are presenting values from late PN patients (n=140). § p≤0.05 using Wilcoxon rank test for 
comparison with admission values. Abbreviations: ADM admission, IQR interquartile range, PN parenteral 
nutrition. 
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Figure 5.5 Effect of early versus late initiation of parenteral nutrition on total and conjugated 
bilirubin levels  
 
The line charts (mean ± SEM) represent the changes from the admission values (referred to as ∆) to day 3 in 
ICU and to day 5 in ICU in plasma total bilirubin and conjugated bilirubin. The grey dots represent the values of 
early PN patients, whereas the open dots are presenting values from late PN patients. * p≤0.05 using the 
Wilcoxon signed rank test for calculations of changes over time; p-values for calculations of differences 
between early and late PN values obtained using Mann-Whitney U test. Correlations between plasma total 
bilirubin levels and conjugated bilirubin levels on admission, on day 3 and day 5 of ICU stay are calculated using 
Pearson’s correlation test. Abbreviations: SEM standard error of the mean, ICU intensive care unit, TBil total 
bilirubin, CBil conjugated bilirubin, ADM admission. 
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Effect of late initiation of parenteral nutrition on gallbladder sludge 
 
Fewer patients in the late PN group developed gallbladder sludge than in the early PN group (37% 
versus 45%; p=0.04)(Table 5.2). Also the incidence of double gallbladder wall tended to be lower in 
the late PN group in comparison with the early PN group (3.3% versus 6.1%, p=0.08). The incidence 
of wall thickening was comparable for both groups (5.7% versus. 6.2%, p=0.8). 
 
Table 5.2 Ultrasonography study of the gallbladder 
 
 Early PN 
(n=420) 
Late PN 
(n=356) 
p-value 
Sludge – n(%) 175 (44.8) 124 (37.3) 0.04 
Wall thickening - n(%) 24 (6.2) 19 (5.7) 0.8 
Double wall - n(%) 24 (6.1) 11 (3.3) 0.08 
 
 
 
Predictive value of bilirubin and bile acids for ICU mortality 
 
The relationship between day 1 bilirubin levels and ICU mortality displays a ‘hockey stick’ shape 
(Figure 5.6): very low levels of bilirubin (<0.36 mg/dL) were associated with a mild increase in 
mortality risk while patients with normal to mildly elevated bilirubin levels (0.36 – 2.39 mg/dL) 
displayed the lowest mortality rates. Only in patients with day 1 bilirubin exceeding 2.40 mg/dL was 
the ICU mortality risk sharply increased. The AROC curve value for day 1 bilirubin to predict ICU 
mortality was 0.597 (calculated in the total study population of 4640 patients). The AROC values of 
admission BAs to predict ICU mortality ranged from 0.455 (tauro-deoxycholic acid) to 0.631 (tauro-
chenodeoxycholic acid), calculated in the bile acid study population (n=280). 
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Figure 5.6 Relationship between plasma total bilirubin levels on day 1 and ICU mortality 
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5.5. Discussion 
 
This study demonstrated that early initiation of parenteral nutrition in critically ill patients 
immediately suppressed plasma bilirubin concentrations. This effect of early PN occurred without 
affecting the plasma concentrations of circulating bile acids. Early PN during critical illness increased 
the levels of cholestatic liver enzymes GGT and ALP and increased the incidence of biliary sludge. The 
latter is in line with the previously observed association between long-term administration of PN and 
the development of biliary sludge in critically ill patients [14] and with the results from a rabbit 
experiment documenting gallbladder distension within 1 week of PN [15]. However, the association 
between PN and biliary sludge in the critical care setting has always been biased by the fact that 
more severely ill patients do not tolerate enteral feeding and rely on PN to maintain caloric intake. 
With the current study, a causal relationship was established. We demonstrated that postponing the 
administration of PN reduced the incidence of gallbladder sludge during critical illness. Biliary sludge 
thus appears to be in part a preventable complication of critical illness as metabolic interventions 
such as tolerating caloric deficits by late PN but also tight blood glucose control [2] synergistically 
lowered the occurrence of gallbladder sludge. Whether the caloric restriction is bringing about this 
effect directly or indirectly through the decreased incidence of ICU acquired infections [8] and 
lowered antibiotic use [16] cannot be delineated from this study. 
 
We previously reported that avoiding early administration of PN during the first week lowered the 
proportion of patients with GGT and ALP levels above 1.5 x upper limit of normality (ULN), our a 
priori definition of cholestasis during ICU stay [2, 8]. While average peak levels of GGT and ALP were 
higher in the early versus late PN group, peak levels still remained below this 1.5 x ULN cut-off. 
Similar subtle differences were seen in plasma ALT levels. While mean levels were higher in the early 
PN group, the proportion of patients with ALT > 3 x ULN did not differ between the treatment groups 
[8]. Taken together, this indicates that overt cholestasis, as seen in chronic TPN administration and 
hyperalimentation, is not frequent in critically ill patients. However, early administration of PN may 
not be well tolerated by the liver during critical illness, causing a relatively mild elevation of liver 
enzymes [6]. 
In contrast with the liver enzymes, peak total bilirubin levels, the archetypical biochemical marker of 
cholestasis during critical illness, remained lower in the patients exposed to the early administration 
of PN. Conversely, patients in the late PN group consistently revealed higher bilirubin levels 
coinciding with a better outcome (shorter ICU stay and less ICU acquired infections). As soon as PN 
was started after 1 week in the late PN group, this difference was mitigated. It confirms our previous 
finding that ‘cholestasis’ defined by bilirubin levels > 3 x ULN is more frequent in the late PN group 
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during the intervention window [8]. Hence, a rise in plasma bilirubin may be an adaptive response in 
the context of caloric restriction during critical illness. Also, in other population studies elevated 
bilirubin levels had a protective effect against coronary artery disease [17] and stroke [18]. 
Hyperbilirubinemia may exert its beneficial effect by improving endothelial function and decreasing 
oxidative stress [19]. Heme oxygenase-1, which is the rate-limiting enzyme in the bilirubin 
production, is protective in endothelial cells against toxicity associated with high glucose and 
oxidative stress [20]. Heme oxygenase knock-out mice have been demonstrated to have a higher 
mortality and more liver and kidney injury during endotoxic shock [21]. Additionally, bilirubin 
administration was shown to attenuate liver and kidney damage in animal models [22, 23]. 
 
However, in this study peak bilirubin levels were associated with ICU mortality risk in a ‘hockey stick’ 
relationship. Very low levels of bilirubin are associated with a mild increase in mortality risk. 
Hyperbilirubinemia on admission only correlated with increased mortality risk when levels exceed 2.5 
-3.0 x ULN. This may explain why bilirubin, analyzed as a continuous variable, has a poor predictive 
power for mortality in non-cirrhotic critically patients [24]. Nevertheless, peak bilirubin levels are still 
used in the most prevalent scoring systems for organ failure such as the SOFA [25], MOD [26] and 
SAPS score [27]. Importantly, peak plasma concentration of bilirubin or GGT/ALP do not seem 
interchangeable in the definition of overt cholestasis [2, 6, 28]. GGT/ALP may be the better indicators 
for cholestasis during critical illness, as these enzymes are believed to reflect ‘cholate stasis’ in the 
bile canaliculi [29]. Alternatively, a higher cut-off for bilirubin as a marker of CLD should be clinically 
validated. 
 
We also observed that the bile acid profile was affected by critical illness, but not by the timing of PN 
initiation. In contrast to Recknagel et al. [24], in our study population, plasma concentration of BAs 
did not predict mortality of critically ill patients better than did plasma bilirubin. The conjugated 
primary bile acids, cholic acid and chenodeoxycholic acid, increased over time while the 
concentrations of unconjugated bile acids were not significantly altered during the course of critical 
illness. Also the conjugated secondary bile acid, deoxycholic acid, was unchanged. This lack of impact 
on circulating BAs may partially be explained by the selection of patients with a surgical 
contraindication to enteral feeding. Consequently, the enterohepatic BA cycle may have been 
impaired. Whether enteral nutrition would exert an additional effect on circulating BAs, cannot be 
addressed as the study was not randomized for enteral nutrition and the specific subset of patients 
for whom BAs were quantified, did not receive any enteral nutrition. Similarly, in the subset of 
patients with a contraindication to enteral feeding, the proportion of conjugated bilirubin was much 
lower than in the overall patient population. The mechanism of this conjugation deficit is not clear 
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and may be related to the higher severity of illness observed in the patient population with a contra-
indication to enteral nutrition. However, unconjugated bilirubin may have more potent anti-oxidative 
properties [30]. Therefore, the mild unconjugated hyperbilirubinemia early in the course of critical 
illness may be a different entity to the pronounced conjugated hyperbilirubinemia typical of 
prolonged critically ill patients, the so called ‘ICU jaundice’ [31]. Nevertheless, the dual role of 
bilirubin during critical illness remains associative from our study data. Only an interventional study, 
in which circulating levels of bilirubin are actively manipulated, can answer whether mild 
hyperbilirubinemia truly protects the patient during critical illness. 
In conclusion, withholding PN and accepting a large caloric deficit during the first week of critical 
illness increased plasma concentrations of bilirubin, lowered plasma levels of GGT and ALP but not of 
BAs, and reduced the incidence of gallbladder sludge. These results suggest that hyperbilirubinemia 
during critical illness does not necessarily reflect cholestasis. Instead hyperbilirubinemia may be an 
adaptive response, which is suppressed by early PN. 
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Supplemental data 
 
 
 
 
 
Supplemental figure 5.1 Total energy intake levels during the EPaNIC study for the subgroup of 
patients selected for analysis of bile acids 
 
Boxes represents daily total caloric intake (glucose, lipids and proteins) expressed as medians with IQR (25
th
-
75
th
 percentiles). The grey bars represent daily caloric intake of patients randomized to receiving early 
parenteral nutrition (early PN), whereas open bars are presenting values from patients randomized to nutrient 
restriction (late PN). The number of patients still in ICU is plotted for each day. Abbreviations: IQR interquartile 
range, PN parenteral nutrition, ICU intensive care unit. 
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Supplemental table 5.1 Baseline characteristics 
 
Patient characteristic Total population Subgroup bile acids Subgroup ultrasonography 
Early PN 
n=2312 
Late PN 
n=2328 
p-value 
Early PN 
n=140 
Late PN 
n=140 
p-value 
Early PN 
n=420 
Late PN 
n=356 
p-value 
Male sex — n (%) 1486 (64) 1486 (64) 0.8 87 (62) 87 (62) >0.9 280 (67) 230 (65) 0.5 
Age - yr 64 ± 14 64 ± 15 0.5 63 ± 14 62 ± 15 0.7 63 ± 15 63 ± 16 0.8 
Weight - kg 76 ±16 75 ± 15 0.05 74 ±17 73 ± 17 0.8 75 ±15 75 ± 16 0.6 
BMI – kg/m2- n(%)   0.3   0.5   0.6 
<20 134 (6) 141 (6)  12 (9) 20 (14)  28 (7) 27 (8)  
20 to <25 854 (37) 890 (38)  65 (46) 55 (39)  172 (4) 139 (39)  
25 to <30 852 (37) 864 (38)  41 (29) 42 (30)  136 (32) 129 (36)  
30 to <40 430 (19) 405 (17)  19 (14) 21 (15)  75 (18) 57 (16)  
≥40 42 (2) 28 (1)  3 (2) 2 (1)  9 (2) 4 (1)  
Diabetes mellitus – n (%) 391 (17) 417 (18) 0.4 17 (12) 19 (14) 0.7 65 (15) 58 (16) 0.8 
Malignancy - n (%) 437 (19) 457 (20) 0.9 86 (61) 83 (59) 0.7 97 (23) 84 (24) 0.9 
NRS score 4 [3-4] 4 [3-4] 0.3 4 [3-5] 4 [3-5] 0.4 4 [3-5] 4 [3-5] 0.9 
Sepsis - n (% ) 510 (22) 505 (22) 0.8 80 (57) 68 (49) 0.2 189 (45) 171 (48) 0.4 
Emergency admission - n (%) 956 (41) 970 (42) 0.8 89 (64) 92 (66) 0.7 306 (73) 266 (75) 0.6 
APACHE II score 23 ± 11 23 ± 10 0.8 27 ± 11 27 ± 11 0.7 31 ± 10 31 ± 9 0.9 
 
Baseline characteristics of the patients of the total study population, the subgroup of patients selected for 
analysis of bile acids and the subgroup of patients who underwent ultrasonographical evaluation of the 
gallbladder. Scores from the Acute Physiology and Chronic Health Evaluation II (APACHE II) reflects severity of 
illness and can range from 0 to 71, with higher scores indicating a greater severity of illness [32]. Scores from 
Nutritional Risk Screening (NRS) range from 0 to 7, with higher scores indicating a higher risk of malnutrition 
[33]. NRS scores are presented as medians with IQR between square brackets. Plus-minus values are means ± 
SD. Percentages may not total 100 because of rounding. Abbreviations: BMI body mass index, SD standard 
deviation, IQR interquartile range. 
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Chapter 6: 
General discussion and conclusions 
 
 
Up to 20% of the patients in the intensive care unit develop cholestatic liver dysfunction (CLD), which 
has been associated with an increased risk of mortality [1-3]. Cholestasis can be defined as a 
decrease in bile flow due to either obstruction of bile flow through mechanical obstruction of the 
hepatic bile ducts or to an inability of the hepatocyte to secrete bile into the bile duct. Mechanical 
obstruction of the extrahepatic bile duct is easily and robustly diagnosed by ultrasonography, but is 
only a rare cause of CLD in critically ill patients. In contrast, critical illness related CLD is 
predominantly due to intrahepatic non-obstructive cholestasis, leading to an intracellular 
accumulation of bilirubin and bile acids.  
 
Although increased concentrations of bile acids inside the hepatocytes are presumed to induce 
cholestatic liver damage, the molecular and biochemical changes underlying CLD are poorly 
characterized and clear diagnostic criteria are lacking. The most widely used definition of CLD in 
clinical practice is a hyperbilirubinemia above 3 mg/dL. However, as a causal link between 
hyperbilirubinemia and worse outcome is missing, it may even be a biochemical epiphenomenon. 
Furthermore, hyperbilirubinemia might represent an adaptive response, as bilirubin can act as an 
endogenous anti-oxidant and may counteract the pro-oxidative effects of BA [4-6]. Additionally, the 
reliability of hyperbilirubinemia as a marker of cholestasis in critically ill patients may be 
questionable, since there are many factors that can influence the levels of bilirubin.  
 
In this thesis, we therefore aimed at further understanding the cholestatic changes at biochemical 
and molecular level during critical illness. The central hypothesis of this doctoral research project 
states that ‘cholestasis’, defined as ‘hyperbilirubinemia’ in the early phase of critical illness is brought 
about by changes in bile acid synthesis and transport and is a protective response of the liver. As 
parenteral nutrition (PN) is assumed to aggravate both CLD and biliary sludge formation [7], we 
further postulate that parenteral nutrition could modify this protective cholestatic response in the 
early phase of critical illness.  
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As explained above, whether hyperbilirubinemia reflects truly cholestasis during critical illness is 
unclear. Therefore, the aim of the first study was to examine a large cohort of critically ill patients to 
gain mechanistic insights into ICU-jaundice, with a focus on bile acids (BAs), hepatocytic transporters 
involved in bile production as well as their regulating nuclear receptors (Figure 6.1).  
 
We studied circulating levels of BAs and bilirubin levels in 130 non-surviving ICU and 20 control 
patients of which liver biopsies were available. In the liver biopsies levels of BAs synthesis enzymes, 
BAs transporters and nuclear receptors were assessed and a histological evaluation of cholestasis 
was performed. 
 
 
 
Figure 6.1  Normal hepato-billiary transport system: simplified scheme 
 
 
Our study of serum analyses indicated that BA levels were highly elevated in critically ill patients on 
their last alive day in ICU. Surprisingly, while bilirubin levels increased 8-fold during critical illness, 
serum total BAs were 11-fold higher. Bilirubin was predominantly conjugated, and the larger increase 
in circulating total BAs mainly consisted of glycine and taurine conjugates of CA and CDCA, whereas 
unconjugated CA and CDCA did not differ from controls. This indicates that the hepatocytes were 
able to conjugate potentially toxic BAs, either de novo synthesized or entero-hepatically recirculated. 
It also suggests that the transport of the conjugated BA towards the apical bile canaliculi is strongly 
shifted to the blood (Figure 6.2). 
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Despite the strongly elevated serum BA levels during critical illness, CYP7A1, the rate limiting step in 
de novo BAs synthesis was only repressed at the mRNA level but not at the protein level. This is in 
line with the absence of increased SHP mRNA expression in ICU-patients, which mediates BA 
repression of CYP7A1 (8). Furthermore, FXR and its heterodimeric partner RXRα, which act in concert 
with SHP to suppress BA synthesis enzymes, were absent from the hepatocytic nucleus, where they 
exert transcriptional activity through direct binding to DNA. This may imply an at least partial loss of 
the sensing of BAs and its feedback regulation of de novo BA production, in light of the increased 
circulating BAs in ICU patients. Alternatively, critical illness may induce elevated BA levels by 
suppressing the BA sensor FXR and maintaining and/or shifting BA-synthesis.  
 
BA and bilirubin are transported by the hepatocyte via the hepatobiliary transporters. The most 
prominent changes in the expression profile of the hepatic BA transporters during prolonged critical 
illness were observed in the basolateral efflux transporters MRP3 and MRP4 (Figure 6.2). Normally, 
MRP3 and MRP4 are expressed at very low levels in hepatocytes, but they become upregulated by 
inflammation and during longstanding cholestasis, presumably shifting transport of BAs back into 
sinusoidal blood for elimination by the kidneys (9). MRP3 correlated well with histological 
bilirubinostasis and serum bilirubin and conjugated BAs levels, suggesting that MRP3 upregulation is 
a compensatory reaction to cholestasis, as has been observed in animal bile duct ligation models of 
cholestasis (10). The upregulation of MRP3 (and MRP4) provides a mechanism to limit hepatocellular 
retention of hydrophobic BAs and other potentially toxic compounds that would normally be 
destined for biliary excretion.  
 
Immunohistochemical expression of BSEP in the hepatocyte canalicular domain was dramatically 
reduced in ICU patients, especially in regions of bilirubinostasis. This decreased BSEP expression 
appears to be a major contributor to the cholestatic phenotype of the prolonged critically ill patient, 
as toxic BAs will accumulate within the hepatocytes.  
 
In contrast to findings from chronic cholestatic disorders (9) and animal models of cholestasis (11) 
and sepsis (12), MRP2, the main canalicular bilirubin transporter, was upregulated during critical 
illness. This seems difficult to reconcile with the elevated serum bilirubin levels. Nevertheless, it may 
fit with the rather moderate increase in serum bilirubin, compared to the changes in serum BA 
concentrations. Besides, bile formation is a secretory process that depends on osmotically active 
solutes, mainly BAs. If the bile flow is hampered as a consequence of retained BAs, bilirubin will also 
be retained, essentially as a biochemical epiphenomenon. Canalicular MDR3 was also upregulated in 
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ICU patients. Given the key role of biliary phospholipids in protecting bile duct epithelium from the 
potentially toxic biliary content, upregulation of MDR3 might also exert a compensatory action, 
protecting the canalicular membrane and biliary epithelium.  
 
 
Figure 6.2  Observed alterations in the hepato-billiary transport system during critical illness 
 
 
In summary, critical illness therefore is hallmarked by a strong increase in serum BA levels. 
Maintenance of BA-synthesis, suppression of FXR/RXRα, with lowering of apical BSEP and elevated 
basolateral MRP3 expression may either be a desired response during critical illness to raise serum 
BA concentrations or it may be a failing feed-back regulation on BA formation and disposition caused 
by cholestasis. 
 
 
To further investigate whether the observed changes in the hepato-billiary transport system have to 
be interpreted as either adaptive or maladaptive, we evaluated cholestatic changes during critical 
illness in the context of a metabolic challenge (artificial nutrition versus nutritional restriction) known 
to influence the hepato-biliary transport system. Critical illness is often accompanied by anorexia and 
a failing of gastro-intestinal function. To prevent caloric deficits, when enteral nutrition is insufficient 
or poorly tolerated, administration of parenteral nutrition (PN) has been recommended, 
commencing as early as the first week of critical illness. PN is claimed to play a role in the 
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development of cholestatic liver dysfunction [13] and the mechanisms behind PN-induced cholestasis 
may include alterations in bile composition and transport as well as direct toxicity by bile acids to the 
hepatocytes. In the second (rabbit) study we therefore aimed to investigate whether fasting, by 
withholding PN, limits cholestatic liver dysfunction in a rabbit model of prolonged critical illness. We 
studied markers of hepatotoxicity, circulating bile acids and the hepatobiliary transport system. 
Critically ill rabbits were randomized to a nutritional strategy either accepting caloric deficits (Fasted, 
n=11) or covering caloric needs by PN (Fed, n=10).  
 
Fasting during prolonged critical illness in rabbits resulted in decreased levels of AST and ALT, 
indicating suppressed parenchymal liver damage. Parenchymal liver damage during critical illness, 
also called hypoxic liver injury [14], is associated with poor outcome in the ICU [15].  
 
In the critically ill rabbits we could not detect bilirubin in the serum, neither by the conventional 
enzymatic essays nor by High Performance Liquid Chromatography. For this reason we focused on 
the bile acids as markers of cholestasis. Withholding PN did not affect the concentration of total bile 
acids in the serum or in the liver. Nevertheless, fasting induced a shift from unconjugated CA and 
DCA to their glycine conjugated forms. This indicates a protective response as conjugated bile acids 
are less toxic than their unconjugated counterparts. It also corroborates our previous observation 
that in critically ill patients the unconjugated bile acids did not differ from controls, but went 
together with a large increase in the concentration of conjugated bile acids. Similarly as in study 1, 
the change in bile acid concentration could not be explained by increased de novo bile acid synthesis 
as the protein expression level of CYP7A1 was unaltered.  
Fasting increased protein expression of the basolateral (MRP3) and the canalicular (BSEP) 
transporter, whereas the canalicular efflux pump MRP2 was suppressed. Gene expression levels of 
the nuclear receptor FXR were lower with fasting and correlated inversely with MRP3. The 
heterodimer partner of FXR, RXRA, was increased with fasting and correlated positively with MRP3. 
As we previously described discrepant responses between the gene and protein expression level, 
interpretation of the data should be done with caution [16]. However, taken that withholding PN 
during critical illness holds a beneficial response, reduced expression of the bile acid sensor FXR, 
maintenance of bile acid synthesis (CYP7A1) and reversal of bile acid transport (MRP3) may 
constitute a protective response.  
 
The rabbit study clearly showed that reduced expression of nuclear bile acid sensors with 
maintenance of bile acid synthesis and reversal of bile acid transport to the blood compartment can 
be seen as a protective response, at least from the standpoint of the liver. However, whether the 
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increased circulating levels of bile acids and bilirubin, and the shift towards more conjugated bile 
acids in critically ill patients holds a survival benefit is not clear yet from this study. 
 
 
We further investigated the relationship between biochemical cholestasis and nutrition in human 
patients. In a large randomized controlled multicenter trial we have recently assessed the outcome 
effect of tolerating a nutritional deficit during the first week in ICU (Late PN), compared with early 
initiation of PN to supplement insufficient enteral feeding (Early PN) [17,18]. Late PN enhanced organ 
function recovery, reduced the incidence of new infections and shortened duration of ICU stay. 
Strikingly, more patients in the late PN group had hyperbilirubinemia above 3 mg/dL, whereas fewer 
late PN patients had a clinically relevant increase in levels of GGT or ALP (19). These observations 
strengthen our postulated hypothesis and the observations made in study 2 that hyperbilirubinemia 
is brought about by an altered hepato-billiary transport system and may represent an adaptive 
response. Therefore, the aim of the third study of this thesis was to compare the effect of late versus 
early PN on circulating bilirubin, BAs and the liver enzymes GGT, ALP, ALT and AST over time. In 
addition, we evaluated the impact of late PN versus early PN on biliary sludge by ultrasonography on 
ICU day 5. 
 
From day 1 after randomization until the end of the 7-day intervention window, bilirubin was higher 
in the late PN than in the early PN group. In the late PN group, as soon as PN was started on day 8, 
bilirubin fell and the two groups became comparable. In contrast, maximum levels of GGT, ALP and 
ALT were lower in the late PN group. Glycine/taurine-conjugated primary BAs increased over time in 
ICU, similarly for the two groups. Fewer patients in the late PN than in the early PN group developed 
biliary sludge on day 5. 
 
Early PN during critical illness increased the levels of cholestatic liver enzymes GGT and ALP and 
increased the incidence of biliary sludge. The latter is in line with the previously observed association 
between long-term administration of PN and the development of biliary sludge in critically ill patients 
[20] and with the results from a rabbit experiment documenting gallbladder distension within 1 week 
of PN [21]. However, the association between PN and biliary sludge in the critical care setting has 
always been biased by the fact that more severely ill patients do not tolerate enteral feeding and rely 
on PN to maintain caloric intake. With the current study, a causal relationship was established. We 
demonstrated that postponing the administration of PN reduced the incidence of gallbladder sludge 
during critical illness. Biliary sludge thus appears to be in part a preventable complication of critical 
illness as metabolic interventions such as tolerating caloric deficits by late PN but also tight blood 
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glucose control [22] synergistically lowered the occurrence of gallbladder sludge. Whether the caloric 
restriction is bringing about this effect directly or indirectly through the decreased incidence of ICU 
acquired infections [23] and lowered antibiotic use [24] cannot be delineated from this study. 
In contrast with the liver enzymes, peak total bilirubin levels, the archetypical biochemical marker of 
cholestasis during critical illness, remained lower in the patients exposed to the early administration 
of PN. Conversely, patients in the late PN group consistently revealed higher bilirubin levels 
coinciding with a better outcome (shorter ICU stay and less ICU-acquired infections). As soon as PN 
was started after 1 week in the late PN group, this difference was mitigated. It confirms our previous 
finding that ‘cholestasis’ defined by bilirubin levels > 3 x ULN is more frequent in the late PN group 
during the intervention window [25]. Hence, a rise in plasma bilirubin may be an adaptive response 
in the context of caloric restriction during critical illness. Also, in other population studies elevated 
bilirubin levels had a protective effect against coronary artery disease [26] and stroke [27]. 
Hyperbilirubinemia may exert its beneficial effect by improving endothelial function and decreasing 
oxidative stress [28]. Heme oxygenase-1, which is the rate-limiting enzyme in the bilirubin 
production, is protective in endothelial cells against toxicity associated with high glucose and 
oxidative stress [29]. Heme oxygenase knock-out mice have been demonstrated to have a higher 
mortality and more liver and kidney injury during endotoxic shock [30]. Additionally, bilirubin 
administration was shown to attenuate liver and kidney damage in animal models [31,32]. 
 
We thus clearly demonstrated that early initiation of parenteral nutrition in critically ill patients 
immediately suppressed plasma bilirubin concentrations without affecting the plasma concentrations 
of circulating bile acids. This lack of impact on circulating BAs may partially be explained by the 
selection of patients with a surgical contraindication to enteral feeding. Consequently, the 
enterohepatic BA cycle may have been impaired. Whether enteral nutrition would exert an 
additional effect on circulating BAs, cannot be addressed as the study was not randomized for 
enteral nutrition and the specific subset of patients for whom BAs were quantified, did not receive 
any enteral nutrition. 
 
 
In conclusion, our findings indeed indicate that ‘cholestasis’ in the prolonged phase of critical illness 
is brought about by changes in the hepato-billiary transport system. Critical illness induces an 
increase in circulating conjugated bile acids and bilirubin, apparently brought about by a reversal of 
normal bile acid transport to the blood. The hepatocyte appears to switch off the nuclear bile acid 
sensors in order to increase circulating bile acids. This energy-saving strategy of the hepatocyte may 
fit well in the concept of MODS as an adaptive, hibernating state. Instead of trying to transport the 
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conjugated bile acids, bilirubin and partially detoxified toxins in the bile against a steep concentration 
gradient at the expense of high ATP-use, it may be better for the liver and the body to accept higher 
circulating concentrations of bile acids, bilirubin and the endo/exotoxins. A simple description of the 
changes in the hepato-biliary transporters and their regulatory network will not improve patient 
outcome. Avoiding the need for the ‘adaptive’ response in the liver may be possible by modifying risk 
factors for development of ICU cholestasis, such as parenteral nutrition.  
 
The observation that lowering or delaying the administration of parenteral nutrition during critical 
illness lowered the peak levels of liver enzymes AST and ALT in rabbits and GGT and ALP in human 
patients shows that nutrient restriction lowers mild hepatocyte lysis and/or cholestasis. 
Furthermore, nutrient restriction also reduced the incidence of biliary sludge. In contrast, bilirubin in 
human patients and conjugated bile acids in rabbits were further increased by nutrient restriction. 
Reversal of the hepato-billiary transport system seems to drive these biochemical changes during 
fasting. These observations strengthen our hypothesis that early mild hyperbilirubinemia may be a 
protective response of the liver and does not necessarily reflect cholestasis. Nevertheless, only an 
interventional study, in which circulating levels of bilirubin are actively manipulated, can answer 
whether mild hyperbilirubinemia truly improves patient-centered outcome during critical illness. 
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Up to 20% of the patients in the intensive care unit develop cholestatic liver dysfunction (CLD), which 
has been associated with an increased risk of mortality. Cholestasis can be defined as a decrease in 
bile flow due to either obstruction of bile flow through mechanical obstruction of the hepatic bile 
ducts or to an inability of the hepatocyte to secrete bile into the bile duct. Mechanical obstruction of 
the extrahepatic bile duct is easily and robustly diagnosed by ultrasonography, but is only a rare 
cause of CLD in critically ill patients. In contrast, critical illness related CLD is predominantly due to 
intrahepatic non-obstructive cholestasis, leading to an intracellular accumulation of bilirubin and bile 
acids. Although increased concentrations of bile acids inside the hepatocytes are presumed to induce 
cholestatic liver damage, the molecular and biochemical changes underlying CLD are poorly 
characterized and clear diagnostic criteria are lacking. The most widely used definition of CLD in 
clinical practice is a hyperbilirubinemia above 3 mg/dL. However, as a causal link between 
hyperbilirubinemia and worse outcome is missing, it may even be a biochemical epiphenomenon. 
Furthermore, hyperbilirubinemia might represent an adaptive response, as bilirubin can act as an 
endogenous anti-oxidant and may counteract the pro-oxidative effects of BA. Additionally, the 
reliability of hyperbilirubinemia as a marker of cholestasis in critically ill patients may be 
questionable, since there are many factors that can influence the levels of bilirubin.  
 
In this thesis, we therefore aimed at further understanding the cholestatic changes at biochemical 
and molecular level during critical illness. The central hypothesis of this doctoral research project 
states that ‘cholestasis’, defined as ‘hyperbilirubinemia’ in the early phase of critical illness is brought 
about by changes in bile acid synthesis and transport and is a protective response of the liver. As 
parenteral nutrition (PN) is assumed to aggravate both CLD and biliary sludge formation, we further 
postulate that parenteral nutrition could modify this protective cholestatic response.  
 
In our first study we examined a large cohort of critically ill patients of whom liver biopsies were 
available to gain mechanistic insights into ICU jaundice, with a focus on bile acids (BAs), hepatocytic 
transporters involved in bile production as well as their regulating nuclear receptors. Critically ill 
patients displayed elevated BA (11-fold) and bilirubin (8-fold) serum levels on their last alive day in 
ICU. Predominantly the conjugated fraction of both bilirubin and bile acids was elevated. This 
indicates that the hepatocytes were able to conjugate potentially toxic BAs, either de novo 
synthesized or entero-hepatically recirculated. Despite the strongly elevated serum BA levels during 
critical illness, CYP7A1, the rate limiting step in de novo BAs synthesis, was not increased. The 
reduced hepatocytic nuclear presence of FXR and RXRα, and a decreased expression of SHP, may 
imply at least a partial loss of the sensing of BAs and its feedback regulation of de novo BA 
production during critical illness. Alternatively, critical illness may induce elevated BA levels by 
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suppressing the BA sensor FXR and maintaining and/or shifting BA-synthesis. Immunohistochemical 
expression of BSEP in the hepatocyte canalicular domain was dramatically reduced in ICU-patients, 
especially in regions of bilirubinostasis. This decreased BSEP expression appears to be a major 
contributor to the cholestatic phenotype of the prolonged critically ill patient, as toxic BAs will 
accumulate within the hepatocytes. The most prominent changes in the expression profile of the 
hepatic BA transporters during prolonged critical illness were however observed in the basolateral 
efflux transporters MRP3 and MRP4. Normally, MRP3 and MRP4 are expressed at very low levels in 
hepatocytes, but they become upregulated by inflammation and during longstanding cholestasis, 
presumably shifting transport of BAs back into sinusoidal blood for elimination by the kidneys. MRP3 
correlated well with histological bilirubinostasis and serum bilirubin and conjugated BAs levels, 
suggesting that MRP3 upregulation is a compensatory reaction to cholestasis. The upregulation of 
MRP3 (and MRP4) provides a mechanism to limit hepatocellular retention of hydrophobic BAs and 
other potentially toxic compounds that would normally be destined for biliary excretion.  
 
To further investigate whether the observed changes in the hepato-billiary transport system have to 
be interpreted as either adaptive or maladaptive, we evaluated cholestatic changes during critical 
illness in the context of a metabolic challenge (artificial nutrition versus nutritional restriction) known 
to influence the hepato-biliary transport system. Critical illness is often accompanied by anorexia and 
a failing of gastro-intestinal function. To prevent caloric deficits, when enteral nutrition is insufficient 
or poorly tolerated, administration of parenteral nutrition (PN) has been recommended, 
commencing as early as the first week of critical illness. PN is claimed to play a role in the 
development of cholestatic liver dysfunction and the mechanisms behind PN-induced cholestasis 
may include alterations in bile composition and transport as well as direct toxicity by bile acids to the 
hepatocytes. In the second study of this thesis, we aimed to investigate whether fasting, by 
withholding PN, limits cholestatic liver dysfunction in a rabbit model of prolonged critical illness. We 
studied markers of hepatotoxicity, circulating bile acids and the hepatobiliary transport system. 
Critically ill rabbits were randomized to a nutritional strategy either accepting caloric deficits or 
covering caloric needs by PN. Fasting during prolonged critical illness in rabbits resulted in decreased 
levels of AST and ALT, indicating suppressed parenchymal liver damage. Fasting also induced a shift 
from unconjugated to conjugated BA. Similarly as in study 1, the change in bile acid concentration 
could not be explained by increased de novo bile acid synthesis. In contrast, fasting increased protein 
expression of the basolateral MRP3 and the canalicular BSEP transporter, whereas the canalicular 
efflux pump MRP2 was suppressed. Gene expression levels of the nuclear receptor FXR were lower 
with fasting and correlated inversely with MRP3. The heterodimer partner of FXR, RXRA, was 
increased with fasting and correlated positively with MRP3. As we previously described discrepant 
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responses between the gene and protein expression level, interpretation of the data should be done 
with caution. However, taken that withholding PN during critical illness holds a beneficial response 
on parenchymal liver damage, the observed changes may constitute a protective response, at least 
from the standpoint of the liver. However, whether the increased circulating levels of bile acids and 
bilirubin, and the shift towards more conjugated bile acids in critically ill patients holds a survival 
benefit is not clear yet from this study.  
 
In a large randomized controlled multicentre trial we have recently assessed the outcome effect of 
tolerating a nutritional deficit during the first week in ICU (Late PN), compared with early initiation of 
PN to supplement insufficient enteral feeding (Early PN). Late PN enhanced organ function recovery, 
reduced the incidence of new infections and shortened duration of ICU stay. Strikingly, more patients 
in the late PN group had hyperbilirubinemia above 3 mg/dL, whereas fewer late PN patients had a 
clinically relevant increase in levels of GGT or ALP. These observations strengthen our postulated 
hypothesis that hyperbilirubinemia may represent an adaptive response. Therefore, the aim of the 
present study was to compare the effect of late versus early PN on circulating bilirubin, BAs and the 
liver enzymes GGT, ALP, ALT and AST over time. In addition, we evaluated the impact of late PN 
versus early PN on biliary sludge by ultrasonography on ICU day 5. Early PN during critical illness 
increased the levels of cholestatic liver enzymes GGT and ALP and increased the incidence of biliary 
sludge. In contrast with the liver enzymes, peak total bilirubin levels, the archetypical biochemical 
marker of cholestasis during critical illness, remained lower in the patients exposed to the early 
administration of PN. Conversely, patients in the late PN group consistently revealed higher bilirubin 
levels coinciding with a better outcome (shorter ICU stay and less ICU-acquired infections). Hence, a 
rise in plasma bilirubin may be an adaptive response in the context of caloric restriction during 
critical illness. Also in other population studies elevated bilirubin levels had a protective effect 
against coronary artery disease and stroke. Hyperbilirubinemia may exert its beneficial effect by 
improving endothelial function and decreasing oxidative stress.  
 
In conclusion, our findings indeed indicate that ‘cholestasis’ in the early phase of critical illness is 
brought about by changes in the hepato-billiary transport system. Critical illness induces an 
immediate increase in circulating conjugated bile acids and bilirubin, apparently brought about by a 
reversal of normal bile acid transport to the blood. The hepatocyte appears to switch off the nuclear 
bile acid sensors in order to increase circulating bile acids. Avoiding the need for the ‘adaptive’ 
response in the liver may be possible by modifying risk factors for development of ICU cholestasis, 
such as parenteral nutrition. The observation that lowering or delaying the administration of 
parenteral nutrition during critical illness lowered the peak levels of liver enzymes AST and ALT in 
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rabbits and GGT and ALP in human patients shows that nutrient restriction lowers mild hepatocyte 
lysis and/or cholestasis. Furthermore, nutrient restriction also reduced the incidence of biliary 
sludge. In contrast, bilirubin in human patients and conjugated bile acids in rabbits were further 
increased by nutrient restriction. Reversal of the hepato-billiary transport system seems to drive 
these biochemical changes during fasting. These observations strengthen our hypothesis that early 
mild hyperbilirubinemia may be a protective response of the liver and does not necessarily reflect 
cholestasis. Nevertheless, only an interventional study, in which circulating levels of bilirubin are 
actively manipulated, can answer whether mild hyperbilirubinemia truly improves patient-centered 
outcome during critical illness. 
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Van patiënten opgenomen op de intensieve zorgenafdeling zal ongeveer 20% cholestatische 
leverdisfunctie (CLD) ontwikkelen, een conditie die sterk geassocieerd is met een verhoogde 
mortaliteit en verlenging van de verblijfsduur. Cholestase wordt gedefinieerd als een verminderde 
galdoorstroming die ofwel veroorzaakt wordt door een mechanische obstructie van de galkanalen 
ofwel doordat de hepatocyt niet langer in staat is om gal te secreteren in de galkanalen. 
Mechanische obstructie is eenvoudig en betrouwbaar te diagnosticeren met behulp van echografie, 
maar is slechts zelden de oorzaak van CLD in kritiek zieke patiënten. CLD gerelateerd aan kritieke 
ziekte is daarentegen voornamelijk te wijten aan intrahepatische non-obstructieve cholestase, die 
leidt tot de accumulering van bilirubine en galzouten in de hepatocyt. Hoewel verondersteld wordt 
dat een verhoogde concentratie aan galzouten in de hepatocyt cholestatische leverschade 
veroorzaakt, is er zeer weinig geweten over de moleculaire en biochemische veranderingen die aan 
CLD voorafgaan. Bovendien ontbreken duidelijke diagnostische criteria. De meest courant gebruikte 
definitie om CLD in te klinische praktijk te definiëren, is een hyperbilirubinemie boven 3 mg/dL. 
Nochtans kon een causaal verband tussen hyperbilirubinemie en toegenomen sterfte nog niet 
worden aangetoond. Hierdoor kan niet uitgesloten worden dat hyperbilirubinemie slechts een 
biochemisch epifenomeen is. Daarenboven zou hyperbilirubinemie ook een adaptieve respons 
kunnen zijn, doordat bilirubine o.a. kan optreden als een endogene anti-oxidant en pro-oxidatieve 
effecten van galzouten kan tegenwerken. Bovendien is de betrouwbaarheid van hyperbilirubinemie 
als klinische merker voor cholestase in kritiek zieke patiënten bediscussieerbaar, aangezien er zeer 
veel factoren zijn die de bilirubine-serumspiegels kunnen beïnvloeden.  
 
Het doel van deze thesis was daarom om cholestatische veranderingen op biochemisch en moleculair 
vlak tijdens kritieke ziekte in kaart te brengen. De centrale hypothese van dit doctoraat stelt dat 
‘cholestase’, gedefinieerd als ‘hyperbilirubinemie’ in de vroege fase van kritieke ziekte veroorzaakt 
wordt door veranderingen in galzuursynthese en -transport en een beschermende respons is van de 
lever. Omdat de toediening van parenterale voeding tijdens kritieke ziekte verondersteld wordt om 
zowel CLD als de vorming van galblaassludge te verergeren, postuleren we bovendien dat de 
toediening van parenterale voeding deze protectieve cholestatische respons zal beïnvloeden.  
 
In de eerste studie hebben we een grote groep kritiek zieke patiënten onderzocht van wie een post-
mortem leverbiopsie beschikbaar was om zo mechanistisch inzicht te verwerven in ICU-gerelateerde 
CLD met een focus op galzouten, de hepatische transporters die betrokken zijn bij galproductie en de 
regulerende nucleaire receptoren. Kritiek zieke patiënten vertoonden verhoogde serumspiegels van 
galzuren (11-voudig) en bilirubine (8-voudig). Voornamelijk de geconjugeerde fractie van zowel 
bilirubine als de galzouten was verhoogd. Dit toont aan dat de hepatocyten nog in staat zijn om 
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potentieel toxische galzouten (ofwel ‘de novo’ aangemaakt ofwel entero-hepatisch gerecirculeerd) te 
conjugeren. Ondanks de sterk verhoogde galzoutspiegels was CYP7A1, het snelheidsbepalende 
enzyme in galzuursynthese, niet verhoogd tijdens kritieke ziekte. De verminderde nucleaire 
aanwezigheid van FXR en RXRA en de verminderde expressie van SHP impliceren mogelijks dat de 
hepatocyt een verstoorde werking vertoont van het feedback-systeem voor galzoutsynthese. 
Anderzijds zou het ook kunnen dat kritieke ziekte juist een verhoging van galzouten veroorzaakt door 
de ‘galzout-sensor’ FXR te verminderen en de galzoutsynthese in stand te houden. 
Immunohistochemische expressie van BSEP langs de canaliculaire zijde van de hepatocyt was sterk 
verminderd bij kritiek zieke patiënten, vooral in gebieden met aantoonbare bilirubinostasis. Deze 
verminderde BSEP-expressie lijkt dan ook een belangrijke rol te spelen in de ontwikkeling van het 
cholestatisch fenotype van de verlengd kritiek zieke patiënt, aangezien dit leidt tot de accumulering 
van toxische galzouten in de hepatocyt. De meest uitgesproken verandering in het expressiepatroon 
van de hepatische galzouttransporters was echter zichtbaar bij de basolaterale efflux-transporters 
MRP3 and MRP4. Normaal worden MRP3 and MRP4 slechts in zeer lage mate geëxprimeerd, maar de 
expressie stijgt tijdens inflammatie en langdurige cholestase, wat kan zorgen voor een ommekeer 
van het galzout-transport naar het bloed om dan via de nieren geëlimineerd te kunnen worden. In 
kritiek zieke patiënten correleerde MRP3 sterk met histologische bilirubinostasis, serum bilirubine en 
geconjugeerde galzuren, wat suggereert dat MRP3-opregulering een compensatoire reactie is op 
cholestase. De opregulering van MRP3 (en MRP4) is inderdaad potentieel een beschermend 
mechanisme om hepatocellulaire opstapeling van hydrofobe galzouten en andere toxische 
producten tegen te gaan die normaal via de biliaire weg afgevoerd worden.  
Om verder te onderzoeken of de geobserveerde veranderingen in het hepato-biliair 
transportsysteem geïnterpreteerd moeten worden als adaptief dan wel maladaptief, hebben we 
cholestatische veranderingen tijdens kritieke ziekte verder onderzocht in de context van een 
metabole uitdaging (artificiële voeding versus nutritionele restrictie) waarvan geweten is dat deze 
het hepato-biliair transportsysteem beïnvloedt. Kritieke ziekte gaat vaak samen met anorexia en een 
falende gastro-intestinale functie. Om een calorisch deficit te vermijden, wanneer enterale voeding 
onvoldoende is of niet wordt getolereerd door de patiënt, wordt vaak overgestapt op het gebruik 
van parenterale voeding. Parenterale voeding zou echter een rol kunnen spelen in de ontwikkeling 
van CLD, het kan een invloed uitoefenen op de samenstelling van gal en op galtransport, alsook meer 
direct op de toxiciteit van galzouten in de hepatocyt. Daarom onderzochten we in de tweede studie 
van deze thesis of ‘vasten’, door geen (par)enterale voeding toe te dienen, de ontwikkeling van CLD 
zou verminderen. We maakten voor deze studie gebruik van een konijnen-model van verlengd 
kritieke ziekte om merkers van hepatotoxiciteit, circulerende galzouten en het hepatobiliair 
transportsysteem te bestuderen. Kritiek zieke konijnen werden gerandomiseerd voor een 
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voedingsschema waarbij ofwel een calorisch deficit werd getolereerd ofwel PN werd toegediend om 
tegemoet te komen aan de dagelijkse normale nood aan calorieën. Vasten tijdens langdurig kritieke 
ziekte veroorzaakte een verlaging in AST en ALT wat aangeeft dat parenchymale leverschade werd 
tegen gegaan. Vasten leidde ook tot een omzetting van ongeconjugeerde tot geconjugeerde 
galzouten in het bloed. Net zoals in de eerste studie kon de veranderde concentratie van 
circulerende galzouten niet verklaard worden door een toegenomen de novo synthese. In tegendeel, 
vasten zorgde voor een verhoogde expressie van de basolaterale transporter MRP3 en de 
canaliculaire BSEP transporter en een verminderde expressie van de canaliculaire effluxpomp MRP2. 
Genexpressie van de nucleaire receptor FXR was verlaagd tijdens vasten en correleerde negatief met 
MRP3. De heterodimeer partner van FXR, RXRA, vertoonde verhoogde expressie tijdens vasten en 
correleerde positief met MRP3. Bij de interpretatie van deze genexpressie-data moet echter rekening 
gehouden worden met eerder beschreven discrepante resultaten tussen genexpressie en 
eiwitexpressie. Desalniettemin, aangezien vasten tijdens kritieke ziekte een gunstig effect had op 
leverschade-parameters, kunnen de geobserveerde veranderingen inderdaad wijzen op een gunstige 
respons, tenminste vanuit het standpunt van de lever. Echter, of de stijging in galzouten en 
bilirubine, en de shift naar meer geconjugeerde galzouten in kritiek zieke patiënten een gunstige 
respons is, kan niet worden besloten uit deze studie.  
In een grote gerandomiseerde studie, uitgevoerd door onze klinische onderzoeksgroep, werd recent 
het effect onderzocht van vroegtijdige toediening van parenterale voeding (vroege PN) versus het 
laattijdig (na 1 week in ICU) opstarten van parenterale voeding (late PN). Late PN versnelde het 
herstel en verminderde de kans op infecties. Verrassend was ook de bevinding dat meer patiënten in 
de late PN groep een hyperbilirubinemie boven 3 mg/dL vertoonden, terwijl minder patiënten in de 
late PN groep een klinisch relevante stijging vertoonden in GGT of ALP. Deze observaties versterken 
onze gepostuleerde hypothese dat hyperbilirubinemie een adaptieve respons zou zijn. Daarom was 
het doel van de laatste studie van deze thesis om het effect van late versus vroege PN na te gaan op 
het tijdsverloop van circulerend bilirubine, galzuren en de leverenzymes GGT, ALP, ALT en AST. We 
evalueerden ook het effect van late PN versus vroege PN op galblaassludge met behulp van 
echografie op de vijfde dag in ICU. Vroege PN tijdens kritieke ziekte verhoogde de serumspiegels van 
de cholestatische leverenzymes GGT en ALP en verhoogde de aanwezigheid van galblaassludge. In 
contrast met de leverenzymes bleef de piek-bilirubinewaarde, wat de meest gebruikte biochemische 
merker is voor cholestase tijdens kritieke ziekte, lager in patiënten in de vroege PN groep. 
Omgekeerd, patiënten in de late PN groep vertoonden hogere bilirubinespiegels gedurende de 
eerste week, en dit terwijl deze patiënten een beter herstel, een kortere ICU verblijfsduur en minder 
vaak nieuwe infecties vertoonden. Dit suggereert dat een stijging in plasma bilirubine een adaptieve 
respons is in de context van calorische restrictie tijdens kritieke ziekte. Ook in andere 
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patiëntenpopulaties werd eerder aangetoond dat verhoogde bilirubinespiegels een protectief effect 
hadden op de bloedvaten van het hart en de hersenen. Hyperbilirubinemie zou gunstig kunnen zijn 
door de endotheelfunctie te verbeteren en oxidatieve stress te verminderen.  
 
 
In conclusie, onze bevindingen geven inderdaad aan dat ‘cholestase’ in de vroege fase van kritieke 
ziekte teweeg gebracht wordt door veranderingen in het hepato-biliair transportsysteem. Kritieke 
ziekte induceert een onmiddellijke stijging in circulerende geconjugeerde galzouten en bilirubine, 
een stijging die teweeg wordt gebracht door een ommekeer van het normaal galzout-transport naar 
het bloed. De levercel lijkt zijn nucleaire galzout-sensoren uit te schakelen om zo te zorgen voor 
verhoogde circulerende spiegels. Men zou de nood voor deze ‘adaptieve’ respons in de lever kunnen 
vermijden door te werken aan de risicofactoren om CLD te ontwikkelen, zoals bijvoorbeeld de 
toediening van parenterale voeding. De observatie dat het uitstellen of verlagen van de toediening 
van parenterale voeding tijdens kritieke ziekte leidde tot verlaagde piekwaarden van de 
leverenzymes AST en ALT in konijnen en GGT en ALP in humane patiënten, geeft aan dat 
voedingsrestrictie zorgt voor een verlaging van milde hepatocyt-lysis en/of cholestasis. Bovendien 
reduceerde voedingsrestrictie ook de ontwikkeling van galblaassludge. Nochtans, voedingsrestrictie 
verhoogde bilirubine in humane patiënten en geconjugeerde galzuren in konijnen. Omkeren van het 
hepato-biliair transport-systeem lijkt de oorzaak van deze veranderingen te zijn. Deze observaties 
ondersteunen dan ook onze hypothese dat een vroege milde hyperbilirubinemie een protectieve 
respons zou kunnen zijn van de lever en niet noodzakelijk cholestase aantoont. Alleen een 
interventionele studie echter, waarin de circulerende spiegels van bilirubine actief worden 
gemanipuleerd, zal een eenduidig antwoord kunnen geven of een milde hyperbilirubinemie het 
ziekteproces van de kritieke zieke patiënt gunstig kan beïnvloeden.  
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